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It is well established that protein interactions with phospholipids, particularly 
phosphoinositides, serve to regulate many different cellular processes.  Due to the charged nature 
of biomembranes, electrostatic interactions are particularly effective between proteins and lipids 
at membrane interfaces where protein oligomerization and locally high charge densities of 
certain phospholipids can contribute significantly to cellular processes. Phosphoinositide 
distributions contribute to organelle identity, recruit proteins important for anterograde or 
retrograde trafficking to the right place at the right time, and directly influence the capacity of 
proteins to signal to downstream partners. Our studies provide evidence in support of the 
importance of protein-lipid interactions in the regulation of epidermal growth factor receptor 
(EGFR) activity and signaling, as well as in biosynthetic trafficking from the endoplasmic 
recticulum (ER) to the plasma membrane (PM).  
The polybasic juxtamembrane (JX) region of EGFR has been proposed to regulate 
protein activity by interacting with the PM and thus preventing tyrosine kinase domain 
activation. We demonstrate that reduction of the net charge of the JX region in wild-type EGFR 
results in constitutive activation of the receptor and conferral of its capacity to transform cells in 
a ligand-independent manner. These capabilities are maintained when the receptor is retained in 
the endoplasmic reticulum. In addition, we show that the polybasic JX region also plays a 
positive role in the response of EGFR to ligand. Receptors in which the net positive charge of the 
JX region is reduced show reduced activation and are deficient in downstream signaling, 
including their capacity to mediate Ca2+ mobilization. 
 
 
 
In addition, we demonstrate that protein-lipid interactions also contribute to proper 
biosynthetic trafficking in cells. We provide pharmacological and molecular genetic evidence for 
the functional requirement of a pool of phosphoinositide 4-phosphate, synthesized by 
phosphoinositide 4-kinase IIIα, for ER to PM protein trafficking. In summary, strategies to 
perturb both protein structure and phospholipid availability provide evidence in support of roles 
for basic amino acid sequences and negatively charged phospholipids in biosynthetic trafficking 
and cellular signaling regulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
BIOGRAPHICAL SKETCH 
 
Kirsten was born November 5, 1985 to Bernard and Lori Elzer in Reading, Pennsylvania. 
She spent her formative years happily following her father around their property “helping” with 
yard work, as well as spending many hours at the kitchen table meticulously completing 
homework under the patient supervision of her mother. These hours paid off in her senior year 
when she graduated Valedictorian of her class at Conrad Weiser High School and was accepted 
for admission to Bucknell University.  
At Bucknell, Kirsten majored in Biology, and in her sophomore year began serving as a 
teaching assistant for the Introductory Biology laboratory course. On her first day as a TA, she 
was assigned to work for Dr. Josef Novak. By the end of that day, Kirsten, was a member of the 
Novak cancer biology laboratory. She spent the next two summers as well as every semester 
until graduation studying the effect of serine protease treatment on neoplastic cell migration and 
falling in love with research.  
Upon graduating Summa Cum Laude from Bucknell and receiving the Phi Sigma Award 
for Excellence in Research, Kirsten was accepted into the Field of Pharmacology at Cornell 
University as a PhD candidate and joined the laboratory of Professor Barbara Baird and Dr. 
David Holowka. Kirsten’s time as a PhD candidate was spent studying the epidermal growth 
factor receptor, in particular, a constitutively active mutant that she discovered is capable of 
maintaining its capacity to transform cells when retained in the endoplasmic reticulum. Aside 
from her academic pursuits in the Baird-Holowka laboratory, she was also the proud creator of 
Team Balowka, the distributor of birthday cards, and the hostess of many memorable Christmas 
parties. 
iii  
Kirsten’s biography would not be complete without mention that while at Conrad Weiser 
High School, she went to the Junior Prom with Matthew Bryant. They traveled to Bucknell 
University together, and were married while they were both PhD candidates at Cornell 
University. In the summer of 2013, they will leave chilly Ithaca for sunny North Carolina where 
Matthew has accepted a position as an Assistant Professor in the Department of Mechanical and 
Aerospace Engineering at North Carolina State University and Kirsten will continue her research 
career as a postdoctoral researcher in the laboratory of Professor Channing Der at University of 
North Carolina at Chapel Hill. If the last eleven years are any indication of their future, they will 
continue to climb, hand in hand, atop mountains, up the rungs of academia, and over the 
rainbow. 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
 
 
 
 
 
 
 
For my father. 
“What we have to do is keep hope alive, 
because without it we will sink.” 
                     -John Lennon 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
ACKNOWLEDGEMENTS 
 
 
 First and foremost I would like to thank my advisors, Barbara Baird and David Holowka, 
for their consistent support and guidance throughout my time as a PhD student. One can not ask 
for a more inspiring mentor than Barbara Baird, and I feel like I will spend the rest of my career 
trying to lead more like her. My friendship with Dave is the most cherished possession that I am 
taking away from Ithaca with me: thank-you for always being there, to help me through the 
tough times as well as share in my greatest accomplishments. 
Richard Cerione has gone above and beyond the typical role of a committee member. I 
thank him for the opportunity to spend a sabbatical in his laboratory, his willingness to 
participate in revising my manuscript, as well as the levity he brought to my committee meetings 
and exams. Thanks also to Clare Fewtrell for providing insightful guidance throughout my 
graduate career as the field-appointed member of my committee.  
I completed my first rotation in the Cerione Laboratory, under the direction of Dr. Marc 
Antonyak. Marc has been a steadfast friend and mentor ever since, and I would like to thank him 
for that, as well as for allowing me to participate as a peripheral member of team TG throughout 
my time at Cornell. 
As a member of the Baird-Holowka lab, I have had the pleasure of sharing my days with 
a number of fantastic people. Early on, Sarah Veatch was a helpful presence and great role 
model. Sarah Shelby’s laid-back, cool brilliance has always impressed me, and while physics 
might always evade me, I hope to try to emulate the laid-back part. I really enjoyed collaborating 
with Amit on the patterned EGF project, and helping Devin take over and move that project 
forward has been a rewarding experience. I will always have a special place in my heart for my 
v  
fellow trafficking subgroup stepchildren: Josh Wilson, Alice Wagenknecht-Wiesner, Jinmin Lee, 
and Norah Smith. Norah has been a great friend who I have missed since her departure and will 
most likely miss even more when we are separated by far more than a mile. 
While I am the first member of my family to receive a PhD, and my parents may not 
understand what exactly I do, they laid the groundwork for me to accomplish this goal and for 
that I am very grateful. I would like to thank my mom for the years she dedicated to monitoring 
my progress at school, and I would like to thank my dad for his steadfast confidence that I was 
making the right decisions and on a clear path. I would also like to thank my parents for the 
Kirstie Leigh and Water’s Edge, the two boats we have owned while in Ithaca, which afforded 
me the luxury of both working and getting away on the weekends. I am also thankful to my 
brother, Sean, for his comedic relief when I need it.   
Last but not least, I would like to thank my husband, Dr. Matthew Bryant, for walking 
beside me for the past eleven and a half years and for the promise of more adventures to come. 
 
 
 
 
 
 
 
 
vi 
TABLE OF CONTENTS 
 
Biographical Sketch ………………………………………………………………   iii 
Dedication ………………………………………………………………………...   iv 
Acknowledgements ……………………………………………………………….    v 
Table of Contents …………………………………………………………………   vi 
List of Figures …………………………………………………………………….  vii 
List of Abbreviations ……………………………………………………………...            viii 
 
Chapter 1. Introduction 
 Protein-lipid interactions facilitate important cellular processes………......          1 
 A historical perspective on EGFR research…………………...…………...       3 
 EGFR proteins structure and activation………………………………........     4 
 Ligand-induced EGFR downstream signaling..............................................     7 
 Constitutively active EGFR mutants and their aberrant signaling................     9 
 Subcellular biosynthetic trafficking is essential for delivery of signaling  
 proteins to the PM.........................................................................................    11 
 Phosphoinositides have specific subcellular distributions and regulate 
 important cellular events, including biosynthetic trafficking........................    14 
 Interplay between PI 4-kinases and PI 4-phosphatases in the regulation of  
 phosphoinositide distributions.......................................................................    16 
 Charge silencing mutagenesis of the polybasic JX sequence of a chimeric 
 FcεRI receptor (αγγ) inhibits its capacity to traffic to the PM......................    19 
 Contributions.................................................................................................    22 
 References.....................................................................................................    24 
 
Chapter 2. Ligand-independent Cell Transformation by an ER-retained EGF  
Receptor Mutant 
 Abstract .........................................................................................................     33  
 Introduction ...................................................................................................    34 
 Materials and Methods ..................................................................................    36 
 Results ...........................................................................................................    41 
 Discussion .....................................................................................................     63 
 References .....................................................................................................    73 
 
Chapter 3. PtdIns4P synthesis by PI4KIIIα and its impact on proper biosynthetic  
protein trafficking. 
 Abstract .........................................................................................................     78 
 Introduction ...................................................................................................    78 
 Materials and Methods ..................................................................................    81 
 Results ...........................................................................................................    84 
 Discussion .....................................................................................................    101 
 References .....................................................................................................   110 
 
Chapter 4. Summary and Future Directions ..............................................................   115 
 
 
vi 
 
 
Appendix 1. Charge-silencing Mutations in the Polybasic Juxtamembrane Sequence  
of the EGF Receptor alter its Capacity for Ligand-Dependent Signaling.  
 Introduction ...................................................................................................   126 
 Materials and Methods ..................................................................................   128 
 Results ...........................................................................................................   130 
 Discussion .....................................................................................................    136 
 References .....................................................................................................   140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
LIST OF FIGURES  
 
1.1 Activation of EGFR by EGF results in the formation of an asymmetric       6  
kinase dimer.    
 
1.2  A subset of intracellular signaling proteins influenced by EGFR.        8 
 
1.3  Intracellular transport pathways.                     13 
 
1.4 Phosphoinositides and organelle identity.                    15 
 
1.5 Current model of the subcellular distribution of cytoplasmic PI 4-kinases.                17 
 
1.6 Charge silencing mutagenesis of the polybasic JX sequence of the a                 20 
chimeric FcεRI receptor (αγγ) inhibits its capacity to traffic to the PM.   
 
2.1 A single point mutation L417H within the N-terminal segment of EGFR                 42 
inhibits its capacity to traffic to the plasma membrane.  
 
2.2 EGFR-GFP Mut R1-6/L417H is retained and intact within the ER.                 44 
 
2.3 EGFR-GFP Mut R1-6/L417H is correctly oriented across the ER                  47 
membrane.  
 
2.4 EGFR Mut R1-6/L417H is retained in the ER when stably expressed in                 50 
NIH 3T3 cells. 
 
2.5 ER-retained EGFR MutR1-6/L417H transforms cells in a growth factor-                52 
 independent manner. 
 
2.6 Anti-EGFR Cetuximab does not inhibit transformation by EGFR Mut                 55 
R1-6/L417H. 
 
2.7 Transformation by ER-retained EGFR Mut R1-6/L417H and its ligand-                     57 
independent phosphorylation are EGFR kinase-dependent. 
 
2.8 Transformation mediated by ER-retained EGFR Mut R1-6/L417H                  60 
depends on PI3K signaling. 
 
2.9 Contribution of Erk pathway to EGFR Mut R1-6/L417H-mediated                  62 
transformation. 
 
2.10 EGFRvIII stably expressed in U87 glioblastoma cells is robustly                  64 
phosphorylated, enhances cell transformation, and is localized to the ER. 
 
 
 
vii 
 
2.11  EGFR-GFP L417A is ER-retained, whereas EGFR-GFP L417F                  68 
shows reduced PM association. 
 
3.1 Robust trafficking of EGFR to the PM is observed upon transferring                85 
expressing cells to 37°C following a14 hr incubation at 24°C. 
 
3.2 Treatment with Brefeldin A inhibits the biosynthetic trafficking of                  87 
EGFR to the PM. 
 
3.3 Treatment with PAO inhibits the biosynthetic trafficking of EGFR to                90 
the PM in a dose dependent manner. 
 
3.4 Treatment with the PI4K inhibitors wortmannin and quercetin prevents                 93 
the biosynthetic trafficking of EGFR to the PM. 
 
3.5 Treatment with PIK-93 does not significantly affect the biosynthetic                 96 
trafficking of EGFR to the PM. 
 
3.6 Transiently expressed EGFR-GFP is retained within the ER of cells                 98 
treated with BFA (5µg/ml) and PAO (2.5µM); whereas in cells treated  
with wortmannin (10µM) retention occurs in the ER and Golgi apparatus. 
 
3.7 Expression of Sac1-GFP inhibits the biosynthetic trafficking of co-               100 
expressed EGFR-GFP to the PM. 
 
3.8 Treatment with PAO inhibits the biosynthetic trafficking of GPI to the PM.             102 
 
3.9 DMS treatment inhibits the biosynthetic trafficking of EGFR to the PM              107 
to a greater extent than treatment with TMS. 
 
A.1 Ca2+ response to EGF for RBL-2H3 cells transiently expressing wt EGFR              132 
and EGFR Mut R1-6. 
 
A.2 EGFR Mut R1-6 receptors exhibit reduced phosphorylation and downstream          134 
signaling through PLC-γ and ERK. 
 
A.3 EGFR Mut R1-6 receptors exhibit negligible phosphorylation of an upper               138 
molecular weight band in response to ligand. 
 
 
 
 
 
 
ix 
LIST OF ABBREVIATIONS 
 
 
αγγ   Chimeric receptors containing extracellular domain of 
FcÇRI alpha subunit, and transmembrane and cytoplasmic 
segments of FcÇRI gamma subunit 
 
 ARF ADP-ribosylation factor    
 
 BAD                            Bcl-2-associated death promoter 
 
 Bcl-2                            B-cell lymphoma 2   
 
 Ca2+   calcium 
 
 CERT   ceramide transfer protein 
 
 DAG   diacylglycerol 
 
 DMS   N,N’-dimethylsphingosine 
 
 EGFR   epidermal growth factor receptor 
 
 EGFRvIII  epidermal growth factor receptor variant-type-three  
 
 EndoH   endoglycosidase H 
 
 ER   endoplasmic reticulum 
 
 ERK   extracellular signal-regulated kinase 
 
 ERGIC  ER-Golgi intermediate compartment 
 
 FAPP   four phosphate adaptor protein 
 
 FFAT   two phenylalanines in an acidic track 
 
 Gab   Grb2-associated binder 
 
 GDP   guanosine diphosphate 
 
 GBM    glioblastoma multiforme 
 
 GFP   green fluorescent protein  
 
 GPI   glycophosphatidylinositol  
 
ix 
 
 
 Grb2   growth factor receptor-bound 2 
 
 GTP    guanosine triphosphate 
 
 GTPase  guanosine triphosphate hydrolase enzyme 
 
 IgG   Immunoglobulin G 
 
 IP3   inositol 1,4,5-trisphosphate 
 
 JX   juxtamembrane 
 
 JNK   c-Jun N-terminal kinase 
 
 MAPK   mitogen activated protein kinase 
 
 mTOR   mammalian target of rapamycin 
 
 NSCLC  non-small-cell lung carcinoma 
 
 OSBP   oxysterol-binding protein 1 
 
 PAO   phenylarsine oxide 
 
 PDI   protein disulfide isomerase 
 
 PDK1   phosphoinositide-dependent kinase 1 
 
 PI   phosphatidylinositol 
 
 PI4KIIα  alpha isoform of type II phosphatidylinositol 4-kinase 
 
 PI4KIIβ  beta isoform of type II phosphatidylinositol 4-kinase 
 
 PI4KIIIα  alpha isoform of type III phosphatidylinositol 4-kinase 
 
 PI4KIIIβ  beta isoform of type II phosphatidylinositol 4-kinase 
 
 PI4P   phosphatidylinositiol-4-phosphate 
 
 PI(4,5)P2  phosphatidylinositol 4,5 bisphosphate 
 
 PIP3   phosphatidylinositol 3,4,5-trisphosphate 
 
 
ix 
 
 PKC   protein kinase C 
 
 PLC   phospholipase C 
 
 PM   plasma membrane 
 
 PNGase F  peptide-N-glycosidase F  
 
 RBL   rat basophilic leukemia  
 
 RER   rough endoplasmic reticulum 
 
 RTK   receptor tyrosine kinase 
 
 Sac1   suppressor of actin mutations 1-like protein 
 
 SER   smooth endoplasmic reticulum 
 
 SNARE  soluble NSF attachment protein receptor  
 
 Sos   son of sevenless 
 
 TGN   trans-Golgi network 
 
 TKD   tyrosine kinase domain 
 
 TMS   N,N’,N”-trimethylsphingosine 
 
 TX   triton 
 
 YFP   yellow fluorescent protein 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
Chapter 1 
 
Introduction 
 
 
1.1 Protein-lipid interactions facilitate important cellular processes. 
 A central theme to what at first might seem like two very different thesis projects is the 
observation that proteins and lipids, specifically phosphoinositides, interact, and that these 
interactions serve to regulate many different cellular processes.  In my first data chapter, I 
describe the generation of an epidermal growth factor receptor (EGFR) mutant in which the net 
charge of the juxtamembrane (JX) region has been reduced from +8 to +3, due to the mutation of 
basic residues to alanines.  This receptor (Mut R1-6) is constitutively active, and we hypothesize 
that this is due to the release of inhibitory protein-lipid interactions that hold the receptor in an 
inactive conformation. In my second data chapter, I demonstrate the importance of 
phosphatidylinositol-4-phosphate (PI4P) in the biosynthetic trafficking of multiple classes of 
proteins. Biosynthetic trafficking of receptors and other transmembrane proteins from the 
endoplasmic reticulum (ER) to the plasma membrane (PM) underlies the capacity of these 
proteins to participate in crucial cellular functions, and this work adds to the body of literature 
describing the importance of phosphoinositides in regulating this process. In the appendix, I 
revisit the EGFR JX mutants and demonstrate that ablating electrostatic interactions of the JX 
region with the PM changes their capacity for ligand-dependent signaling as compared to wt 
EGFR. 
 The concept of protein regulation by phosphoinositides is becoming well established in 
the literature. Phosphatidylinositol 4,5 bisphosphate (PI(4,5)P2) serves important cellular 
functions as the upstream source of three second messengers. Hydrolysis of PI(4,5)P2 by 
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phospholipase C (PLC) family members results in the generation of inositol 1,4,5-trisphosphate 
(IP3) and diacyglycerol (DAG), and phosphorylation by PI3-kinase produces 
phosphatidylinositiol 3,4,5-trisphosphate (PIP3). PI(4,5)P2 also serves independently as a second 
messenger itself (Hurley and Meyer, 2001; Hilgemann et al., 2001). PI(4,5)P2 has been 
implicated in cytoskeletal organization (Raucher et al., 2000; Yin and Janmey, 2003), membrane 
trafficking and exocytosis (Martin, 2001; Wenk and De Camilli, 2004), as well as in regulation 
of ion channel function (Logothetis et al., 2010). Furthermore, there have been several reports of 
PI(4,5)P2 existing in functionally and spatially distinct pools in the PM that support specific 
signaling platforms (Lui et al., 1998; Johnson et al., 2008; Vasudevan et al., 2009; Calloway et 
al., 2011). PI(4,5)P2 has also been shown to regulate epidermal growth factor receptor activation 
(Michaildis et al., 2010; see below). 
 PI4P, traditionally viewed as serving only as the precursor for PI(4,5)P2, has also more 
recently been appreciated as an independent regulator of cellular functions. PI4P is primarily 
enriched in the Golgi apparatus in cells (De Matteis and D’Angelo, 2007) and thus has been 
implicated as a regulator of Golgi to PM secretion (Walch-Solimena and Novick, 1999; Bruns et 
al., 2002). PI4P has also been reported as necessary to promote COPII-mediated ER export by 
assisting in Sar1-induced COPII nucleation (Blumental-Perry et al., 2006).  
 Herein, I will review the vast EGFR literature in a way that highlights the studies most 
important for providing the context for my own work, beginning with a brief history of EGFR 
biology. I will then provide an overview of EGFR structure and the mechanism of its activation 
by ligand. Next, I will review mutations which result in EGFR constitutive activation, 
highlighting examples in which trafficking of the mutant protein is also aberrant. In the second 
half of the chapter, I will review the importance of phosphoinositides in regulation of cellular 
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signaling and biosynthetic trafficking. I will begin by highlighting the subcellular distribution of 
the different phosphoinositide species in cells, and then review the PI-kinases and PI-
phosphatases that maintain this varied distribution. I will then focus on pharmacological and 
genetic methods that have been developed to interfere with this regulation. My hope is that this 
introduction will allow the reader to better appreciate the contribution of the following data 
chapters to the fields of EGFR and phosphoinositide biology, respectively. 
 
1.2 A historical perspective on EGFR research. 
The concept of signal generation from phosphorylated receptor tyrosine kinases (RTKs) 
that are activated by their respective ligands at the PM has been a tenet in the field of receptor 
biology since the early 1980’s (Ushiro and Cohen, 1980). The findings that many epithelial 
tumors overexpress RTKs, particularly members of the ErbB family, and that they are key 
contributors in cancer progression (Clark et al., 1984), led to an explosion of a field that 
continues to grow at a rapid pace today. By the end of that decade it was understood that, like 
overexpression, mutations in RTKs can lead to dysregulated signaling. EGFR is the prototypic 
RTK. 
EGF, a ligand that activates EGFR, was isolated and purified by Stanley Cohen in 1962. 
Within three years he furthered this discovery by showing that this molecule could stimulate the 
growth of epithelial cells (Cohen, 1965); these important discoveries led to his receipt of the 
Nobel Prize in Physiology and Medicine, which he shared with Rita Levi-Montalcini for her 
characterization of the related factor, nerve growth factor. It was not until 1975 that the presence 
of specific binding sites for EGF on the surface of cells was proposed by Graham Carpenter 
(Carpenter et al., 1975), a member of Cohen’s lab at the time. In time they showed that this 
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binding site was actually a 170-kda PM-localized RTK (Carpenter et al., 1978; Ushiro and 
Cohen, 1980). 
 Throughout the 1980’s, as researchers sought to better characterize the function of EGFR 
and other RTKs, it was routinely demonstrated that EGFR was overexpressed in a number of 
epithelial tumors, implicating its dysregulation in the biology of cancer (See Section 1.5). It is 
interesting to note that the full appreciation of EGFR signaling in normal tissues lagged behind 
its implication in cancer. In the mid-nineties it was demonstrated that EGFR knock-out in mice 
resulted in embryonic lethality or severe developmental defects in multiple organs (Threadgill et 
al., 1995). The abnormalities associated with EGFR deficiency confirmed that it is required for 
normal epithelial development. 
 
1.3 EGFR protein structure and activation. 
 EGFR is a Type I transmembrane glycoprotein consisting of an extracellular ligand-
binding segment, a single transmembrane segment, and an intracellular segment that contains a 
JX region, a tyrosine kinase domain (TKD), and a C-terminal tail (Figure 1.1). While the 
receptor has not been crystalized in its entirety, multiple structures of pieces of the receptor with 
or without ligands or inhibitors have been reported. The large extracellular domains are 
responsible for binding to ligands including EGF, transforming growth factor α, amphiregulin, 
betacellulin, epigen, epiregulin, and heparin binding EGF-like growth factor (Harris et al., 2003). 
The extracellular domain consists of two homologous ligand-binding domains (domains I and 
III) as well as two cysteine-rich domains (domains II and IV). In the unliganded state, domain II 
participates in extensive intramolecular interactions with domain IV (Ferguson et al., 2003). 
Upon binding to ligand, the extracellular domain undergoes a dramatic conformational change, 
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through which the dimerization arm, located in domain II, is exposed and thus free to associate 
with domain II of the interacting receptor to form a completely receptor-mediated dimer (Figure 
1.1; Ogiso et al., 2002; Garrett et al., 2002).  This is in stark contrast to many other RTK dimers 
that rely on the ligand to provide much of the dimer interface (Hubbard and Till, 2000). 
 While the structure of the EGFR TKD has been extensively studied, little information is 
known about the presumably unstructured last ~190 amino acid C-terminal tail containing many 
of the phosphorylation sites important for downstream signaling (Linggia and Carpenter, 2006). 
The JX region of EGFR, which also lagged behind the TKD in terms of its structural 
characterization, has recently emerged as a key regulator of receptor function, and the current 
model for TKD activation can no longer be discussed without describing its involvement. The 
role of the JX region of EGFR in receptor activation differs from many other RTKs in that the JX 
region plays an activating role rather than an inhibitory role (Thiel and Carpenter, 2007). 
 Activation of the EGF TKD is also distinctive in that, rather than being mediated by 
phosphorylation, it is triggered by allosteric interactions between the TKDs as they form an 
asymmetric dimer in which one monomer, the activator, activates the receiver TKD (Zhang et 
al., 2006). The more C-terminal half of the JX region (JM-B;Figure 1.1) of the receiver TKD 
forms a clasp that interacts with the C-terminal portion of the activator TKD (Red Brewer et al., 
2009; Jura et al., 2009). The more N-terminal half of the JX region (JM-A; Figure 1.1) stabilizes 
this interaction via the formation of an antiparallel helical dimer (Jura et al., 2009). TKD 
activation is followed by transphosphorylation of the C-terminal tails of two interacting 
receptors. EGFR TKDs can serve as both activators and receivers; interestingly, the kinase dead 
ErbB3 retains the capacity of serving as an activator TKD (Zhang et al., 2006). This observation  
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From: Jura et al. (2009) Cell 137(2):1293-1307.  
 
 
Figure 1.1. Activation of EGFR by EGF results in the formation of an asymmetric kinase dimer.  
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mechanistically explains how ErbB3 can pair with and activate other ErbB family members 
(Yarden and Sliwkowski, 2001). The JX region of EGFR has also been implicated in maintaining 
the unliganded receptor in an inactive state. Recent evidence suggests that the basic residues in 
the N-terminal JX region electrostatically associate with negatively charged phospholipids to 
facilitate insertion of adjacent hydrophobic leucine side chains into the PM bilayer in inactive 
EGFR. The leucine side chains are then expelled during formation of the helical dimer in the 
active state (Endres et al., 2013; Arkhipov et al., 2013). 
 
1.4 Ligand-induced EGFR downstream signaling. 
 The phosphorylated tyrosines on the C-terminal tail of EGFR act as docking sites for 
adaptor molecules that link the receptor to downstream pathways. A multitude of pathways 
emanate from EGFR. Herein, I will focus on the Ras/MAPK/ERK pathway, the PI3K-Akt 
pathway, and EGFR signaling through PLCγ (Figure 1.2). 
 EGFR signaling through Ras begins with the recruitment of the adaptor protein growth 
factor receptor-bound 2 (Grb2) to the phosphorylated receptor (Lowenstein et al., 1992). Grb2 
recruits the protein son of sevenless (Sos), which acts as a guanine nucleotide exchange factor 
for Ras, thus transitioning it to its GTP-bound, active state (Wolfman and Marcara, 1990; 
Downward et al., 1990).  Ras proteins communicate with more than 20 different downstream 
signaling partners, the most prominent of these being the Raf protein kinase family. Raf activates 
MEK and ERK among other signaling proteins to drive cell proliferation (Marshall, 1995; 
Ramos, 2008). 
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Figure 1.2. A subset of intracellular signaling proteins influenced by EGFR. 
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 Phosphatidylinositol 3-kinase (PI 3-kinase) is activated by virtually all RTKs 
(Schlessinger, 2000). One group of PI3-kinases exists as dimers consisting of a regulatory p85 
subunit and a catalytic p110 subunit. The p85 subunit is recruited to phosphorylated EGFR via 
the scaffold protein Grb2-associated binder (Gab) (Kong et al., 2000). Activated PI3-kinase 
phosphorylates PI(4,5)P2 to generate PI(3,4,5)P3, which in turn recruits a variety of non-receptor 
tyrosine kinases to the PM including PDK1 and Akt (Rameh and Cantley, 1999; Czech, 2000). 
Activation of Akt leads to cell survival and the evasion of apoptosis via phosphorylation and thus 
inactivation of the protein, BAD, which blocks its complex formation with apoptotic proteins 
Bcl-2 and Bcl-xl (Datta et al., 1999). Akt also phosphorylates and activates the transcription 
factor, FKHRI, which inhibits pro-apoptotic gene expression (Brunet et al., 1999). Furthermore, 
Akt can phosphorylate tuberin, which leads to activation of the mammalian target of rapamycin 
(mTOR) complex, a master regulator of cell growth (Manning and Cantley, 2003). 
 Activation of EGFR leads to phosphorylation of the receptor at tyrosine residue 992 and 
subsequent recruitment of PLCγ (Emlet et al., 1997). Upon phosphorylation and activation, PLCγ 
hydrolyzes PI(4,5)P2 to form the second messengers IP3 and DAG (Berridge, 1983). IP3 interacts 
with the IP3 receptor in the ER to mediate release of Ca2+ from ER stores. The released Ca2+ 
binds to calmodulin, which in turn activates Ca2+/calmodulin dependent protein kinases. 
Meanwhile, DAG, in concert with Ca2+, activates protein kinase C (PKC).  PKC activation leads 
to phosphorylation and activation of transcription factors (Karin and Hunter, 1995). 
 
1.5 Constitutively active EGFR mutants and their aberrant signaling. 
 EGFR plays important roles in cell differentiation, proliferation, and epithelial 
organogenesis (Carpenter, 2000). Changes in its expression and regulation, due to gene 
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duplication events (Xu et al., 1964; Lidermann et al., 1985; King et al., 1985; Kraus et al., 1987), 
in-frame deletions (Humphrey et al., 1988; Lynch et al., 2004), and point mutations (Red Brewer 
et al., 2009; Lynch et al., 2004) have been linked to tumor progression. Oncogenic mutations in 
EGFR seem to cluster in the ligand binding domain and in the TKD, two regions that are 
specifically important for functional regulation of the receptor. 
 The activity of the EGFR TKD is tightly controlled by conformational changes that occur 
in response to ligand binding. Mutations within this domain occur most often in non-small-cell 
lung carcinomas (NSCLCs) and can destabilize the inactive state of the TKD, hence leading to 
constitutive activation (Landau and Ben-Tal, 2008). The most common mutations that occur in 
this region include small deletions in the phosphate binding loop, and point mutations, such as 
the prototypical L858R mutation located in the activation loop (Paez et al., 2004; Greulich et al., 
2005). Paradoxically, while these mutations constitutively activate the TKD, certain ones also 
sensitize it to inhibition with small molecules such as gefitinib or erlotinib (Carey et al., 2006; 
Yun et al., 2007).  
 As described above, formation of stable EGFR dimers follows binding of ligand to the 
extracellular domain of the receptor.  While this process is necessary for activation, it can also be 
viewed as regulatory: When EGF is not bound, the receptor exists in a conformation that does 
not lead to signaling. The viral EGFR homologue, v-ErbB, which induces erythroblastosis in 
birds, completely lacks the EGF binding domain.  This protein constitutively dimerizes, which 
leads to its constitutive kinase activation and facilitation of cellular transformation (Downward et 
al., 1994). A similarly mutated and constitutively active receptor, EGFR variant III (EGFRvIII), 
is found frequently in human glioblastoma multiforme (GBM), as well as in NSCLC, breast, and 
ovarian cancers (Huang et al., 1997). This mutant results from deletion of exons 2-7 of EGFR 
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(801 bp), which encompasses much of the ligand-binding domain. Interestingly, aside from 
being constitutively active, both v-ErbB and EGFRvIII have been reported to mislocalize to 
intracellular membranes (Privalsky and Bishop, 1984; Ekstrand et al., 1995; Gupta et al., 2010). 
Apart from mutants that contain large in-frame deletions, some point mutations within the 
ligand-binding domain have been reported to constitutively activate the receptor (Lee et al., 
2006). However, these point mutations do not exhibit the trafficking defect. It is also interesting 
to note that while the activated wt EGFR signals through many downstream proteins (Figure 
1.2), EGFRvIII exhibits downstream signaling primarily through the PI3K pathway (Moscatello 
et al., 1998) to JNK (Antonyak et al., 1998). The mechanism by which this particular dependence 
on one signaling pathway is achieved is not currently known. 
 
 
1.6 Subcellular biosynthetic trafficking is essential for delivery signaling 
proteins to the PM. 
  
 The secretory pathway in eukaryotic cells mediates the delivery of proteins, 
carbohydrates, and lipids to the cell surface.  It consists of three major hubs: the ER, the Golgi 
apparatus, and the PM (Figure 1.3). Protein synthesis occurs at the ER, where, following 
synthesis proteins are packaged into COPII coated vesicles that fuse to form the ER-Golgi 
intermediate compartment (ERGIC) before fusing to the cis-Golgi (Klumperman et al., 1998).  
Following maturation through the Golgi stacks, the proteins reach the trans-Golgi network 
(TGN), where they are sorted for delivery to the PM. The distributions of many of these 
organelles were originally characterized by electron microscopy-based studies of fixed cells 
(Palade, 1975). Later, genetic and biochemical studies defined the machinery necessary for these 
events (Schekman and Orci, 1996; Rothman and Wieland 1996). More recently, studies of the 
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dynamics and kinetics of the process have been made more accessible with the use of live cell 
microscopy of fluorescently tagged proteins (Lippincott-Schwartz, 1998). 
 The ER is the starting point of the secretory pathway. It is composed of two subsets: the 
ribosome-covered rough endoplasmic reticulum (RER) responsible for protein synthesis and 
trafficking, and the smooth endoplasmic reticulum (SER), which is thought to be responsible for 
additional ER-functions such as Ca2+ regulation. Following insertion into the ER membrane, 
proteins encounter both luminal and cytoplasmic chaperone proteins; if a protein is misfolded, it 
is retained and degraded, and in this way the ER serves as point of quality control for the 
biosynthetic pathway (Hammond and Helenius, 1995). Proteins exit the ER at specialized 
domains called ER-exit sites, where vesicles budding from the ER are covered in a protein coat 
complex, COPII.  COPII coat assembly begins with Sec-12 mediated GDP/GTP exchange on the 
GTPase Sar1 (Barlowe and Schekman, 1993).  When Sar1 is bound to GTP it recruits the 
Sec23/24 protein complex (Yoshihisa et al., 1993), which in turn recruits the Sec13/31 complex, 
which polymerizes the coat to form the final COPII bud (Matsuoka et al., 1998). Upon leaving 
the ER, COPII vesicles are thought to fuse and become the ERGIC compartment (Klumperman 
et al., 1998). 
 When proteins reach the cis-Golgi apparatus, they first must pass through another round 
of quality control. If a protein is misfolded, it is trafficked back to the ER in COPI-coated 
vesicles (Pelham, 1994); COPI-mediated retrograde trafficking can occur throughout the Golgi 
stack. Correctly folded proteins move through the elaborate network of Golgi cisternae, which 
contain many different glycolipid and glycoprotein-processing enzymes. Once a protein has 
matured through a stack of Golgi cisternae it reaches the TGN. Exit from this structure involves 
sorting into distinct pathways that lead to different compartments within the cell, including the  
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From: Bonifacino JS and Glick BS (2004) Cell 116(2):153-166. 
 
Figure 1.3. Intracellular transport pathways. The biosynthetic pathway is described in the text. 
Also, depicted here is the endosomal/lysosmal pathway in which proteins undergo retrograde 
transport into the cell and are either recycled back to the PM or degraded in the lysosome. 
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endosomal system and the PM (Keller and Simmons, 1994). 
 
1.7 Phosphoinositides have specific subcellular distributions and regulate 
important cellular events, including biosynthetic trafficking. 
 
Not addressed in the above overview of biosynthetic protein trafficking is the intricate 
regulation of membrane budding, trafficking, and fusion events by proteins. Coat proteins (e.g. 
COPI and COPII) are essential for membrane budding whereas SNARE proteins (e.g. syntaxin 
and synaptobrevin) regulate membrane fusion. In addition, two entire families of small GTPases, 
Rab- and Arf-GTPases, have evolved to regulate the process of vesicular trafficking. More 
recently, it has been appreciated that the phosphorylated derivatives of phosphatidylinositol (PI), 
or phosphoinositides, mediate the interactions of protein regulators of vesicular trafficking with 
target membranes. 
Studies of phosphoinositides have shown that these molecules possess distinct biological 
functions and are localized to selective organelles (reviewed by Di Paolo and De Camilli, 2006). 
Due to variable phosphorylation of hydroxyl groups on their inositol rings, seven different 
interconvertable phosphoinositide species exist in cells, including PI4P and PI(4,5)P2. Each 
phosphoinositide species is enriched in specific intracellular membranes (Figure 1.4); for 
example, PI(4,5)P2 is highly localized to the inner leaflet of the PM and PI4P is enriched at the 
Golgi complex.  
PI(4,5)P2 is a well-established regulator of multiple cellular processes including  vesicle 
trafficking and phagocytosis (Coppolino et al., 2002). Although the clathrin adaptors AP-1 and 
AP-2 recognize some of the same cargo proteins, the AP-2 complex is targeted to the PM due the 
concentration of PI(4,5)P2 at this subcellular location (Honing et al., 2005). PI(4,5)P2 also 
regulates endocytosis via interactions with dynamin (Wenk and De Camilli, 2004). Dynein  
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Figure 1.4. Phosphoinositides and organelle identity. Phosphoinositides are selectively and 
heterogeneously distributed throughout the cell and can be used as markers for different 
organelles based on their discrete subcellular distribution. 
 
 
 
 
From Le Roy and Wrana (2005) Nat Rev Molec Cell Biol 6(2):112-126.!
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controls the membrane fission reaction, through interactions with the actin cytoskeleton, which is 
involved in all types of membrane endocytosis (Engqvist-Goldstein and Drubin, 2003). PI3P and  
PI(3,5)P2 are essential for endosomal regulation, PI3P is a marker for early endosomes, and its 
presence is necessary for the recruitment of endosomal proteins (Birkeland and Stenmark, 2004).  
PI4P is particularly important for the regulation of protein trafficking. For example, PI4P 
is required for COPII-mediated export of proteins at ER exit sites (Blumental-Perry et al., 2006), 
and, by interacting with CERT, OSBP, and FAPP lipid transfer proteins (collectively termed 
COFs), PI4P also plays a role in sphingolipid and sterol metabolism (D’Angelo, 2008). Also, 
PI4P regulates the targeting of the clathrin adaptor AP-1 complex to the Golgi, thus participating 
in Golgi to PM trafficking (Wang et al., 2003).  
 
 
1.8 Interplay between PI 4-kinases and PI 4-phosphatases in the regulation of 
phosphoinositide distributions. 
 
Organelle-specific phosphoinositide distributions are maintained by the tight regulation 
of cytoplasmic PI-kinases and PI-phosphatases. Four distinct PI 4-kinases have been described in 
mammalian cells (Figure 1.5), including type II (PI4KIIα and PI4KIIβ) and type III (PI4KIIIα 
and PI4KIIIβ) kinases (Balla and Balla, 2006). The type II PI 4-kinases are palmitoylated 
(Barylko et al., 2001) and thus strongly membrane associated, particularly in the trans-Golgi 
apparatus (Wang et al., 2003) and to a lesser extent in endosomes (Balla et al., 2004). PI4KIIIβ is 
primarily Golgi-localized (Wong et al., 1997) mostly due to its coincidence detection with Arf1, 
a small GTP-binding protein (Godi et al., 1999). While the molecular details of how these 
enzymes are linked to Golgi-derived biosynthetic transport have not been entirely elucidated,  
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Figure 1.5. Current model of the subcellular distribution of cytoplasmic PI 4-kinases. Because 
such a large amount of cellular PI4P localizes to the Golgi, some PI4P may reach the PM via 
vesicular transport. The primary membrane that PI4KIIIα localizes to has not been definitively 
established. 
 
 
 
 
Adapted from Szentpetery et al. (2010) PNAS, 107(18):8225-30.!
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they have all been implicated with proper Golgi function and secretion (Balla and Ball, 2006). 
The localization of PI4KIIIα is not well understood. In mammalian cells, PI4KIIIα was 
originally reported to localize to the ER based on immunofluorescence (Wong et al., 1997).  
However, more recent functional studies have questioned this localization (Balla et al., 2008; 
Nakatsu et al., 2012) and propose that this cytoplasmic enzyme most frequently associates with 
the PM. The only lipid phosphatases with enzymatic activity towards PI4P are phosphoinositide 
phosphatases that contain Sac1 homology domains (Guo et al., 1999). The Sac1 protein is a 
transmembrane protein that localizes to the ER and Golgi membranes, and thus can perform 
organelle-specific roles in lipid signaling (Konrad et al., 2002).   
 The cellular functions of the different PI 4-kinases have been elucidated, in part, by the 
characterization of a number of different pharmacological inhibitors of these enzymes. 
Phenylarsine oxide (PAO) is a well-established inhibitor of PI 4-kinases (Wiedemann et al., 
1996), which, when applied at very low micromolar concentrations, can selectively inhibit the 
PI4KIIIα isoform (Balla and Balla, 2006). Likewise, PI4KIIIβ can be selectively inhibited with 
PIK-93, or phenylthiazole (Knight et al., 2006).  Two less isoform-specific PI4-kinase inhibitors 
are wortmannin and quercetin. Nanomolar concentrations of wortmannin have been shown to 
inhibit PI3-kinase (Arcaro and Wymann, 1993), whereas significantly higher micromolar 
concentrations are needed to inhibit PI4-kinases (Downing et al., 1996; Meyers and Cantley, 
1997). Quercetin has been shown to generally inhibit kinases by competition with ATP for the 
active site (Middleton et al., 2000), and low micromolar concentrations can selectively inhibit PI-
kinases (Santos et al., 2013). More recently, genetic approaches such as overexpression of PI-
kinases and PI-phosphatases have been employed to modulate phosphoinositide levels in cells. 
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Szentpetery et al., 2010 described a useful drug-inducible molecular approach to more 
specifically target the effects of Sac1 phosphatase activity to a precise intracellular membrane. A 
similar technique has been used to deplete PIP2 at the PM with synaptojanin (Chang-Ileto et al., 
2011), and many other laboratories are modifying this technique to target different pools of 
phosphoinositides throughout the cell (Chang-Ileto et al., 2012). 
 
1.9 Charge silencing mutagenesis of the polybasic JX sequence of a chimeric 
FcεRI receptor (αγγ)  inhibits its capacity to traffic to the PM.  
 
 Our laboratory’s interest in the interactions of phosphoinositides with polybasic JX regions 
of proteins was generated by our finding that PIP2 positively regulates stimulated FcεRI receptor 
phosphorylation (Vasudevan, 2008). A candidate sequence for interactions between FcεRI and 
PIP2 is the polybasic JX region of the γ-subunit of the receptor. To investigate this possibility, we 
utilized a single chain chimeric receptor consisting of the IgE-binding extracellular domain of 
the human α-subunit fused to the transmembrane and cytoplasmic domains of the γ-subunit (αγγ) 
previously constructed by our laboratory (Gosse et al., 2005).  In the context of this chimera, we 
mutated the putative PIP2-binding basic residues of the γ-cytoplasmic domain to alanines (Figure 
1.6A).    
  Based on quantitative flow cytometry (Figure 1.6B), mutation of one or two of the basic 
residues caused small reductions in surface expression, but mutation of three of the four basic 
residues within this region completely abolished surface expression of αγγ.  Rather than 
trafficking to the PM, the receptor was retained intracellularly, largely in the ER (Figure 1.6C). 
These results precluded a systematic investigation of the role of this polybasic sequence in FcεRI 
interactions with PIP2 at the PM, but they suggested that the basic residues in the JX region of 
αγγ are important for its trafficking to the PM. 
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Figure 1.6. Charge silencing mutagenesis of the polybasic JX sequence of the a chimeric FcεRI 
receptor (αγγ) inhibits its capacity to traffic to the PM. (A) Wild type and mutant αγγ constructs. 
The JX sequence is shown: basic amino acids are in bold and mutated residues are underlined. 
(B) Quantification of the effects of mutation of the polybasic JX domain of the αγγ receptor on 
biosynthetic trafficking. Transiently expressing CHO cells were labeled with Alexa 488 mouse 
IgE for 30 min at 37°C, then fixed, permeabilized and labeled with anti-human FcεRIα Ab, 
followed by Alexa 546-anti rabbit IgG and analyzed using flow cytometry to determine the ratio 
of PM-localized Α488 fluorescence to total A546-αγγ fluorescence. Data from mutants is 
normalized to wt, and error bars indicate ± SD of three independent experiments in which >3,500 
cells expressing each construct were analyzed. (C) Confocal imaging of wt and mutant 
αγγ constructs in CHO cells. Transiently expressing cells were labeled with Alexa 488-mouse 
IgE for 30 min at 37°C, then fixed, permeabilized and labeled with rabbit anti-human FcεRIα 
subunit antibody, followed by Alexa546-anti-rabbit IgG.  
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 EGFR is a Type I transmembrane protein that contains a polybasic JX domain analogous to 
that of FcεRIγ (Sato et al., 2006). Our studies with EGFR began when we performed similar 
mutagenesis on this receptor to test the generality of our hypothesis that such basic residues are 
important for ER to PM trafficking.  Following the line of evidence that originally led to our 
mutation of the polybasic JX region of EGFR, one can appreciate that the observed ER-retention 
that occurred when six of the nine basic residues were mutated to alanines (Figure 2.1), was 
originally viewed as support of our αγγ data. Our guiding hypothesis at that time, that 
electrostatic interactions between the basic regions of proteins and acidic phospholipids were 
important for proper biosynthetic trafficking, is what led us to study both the role of the 
polybasic JX region of EGFR in its signaling (Chapter 2) and the importance of PI4P in ER to 
PM trafficking (Chapter 3). 
 
1.10 Contributions 
The juxtamembrane region of EGFR has recently emerged as a key regulator of receptor 
function (Red Brewer et al., 2009; Jura et al., 2009; Arkhipov et al., 2013). In Chapter 2 of this 
dissertation, I demonstrate that reduction of the net charge in the JX region of wild-type EGFR 
results in constitutive activation of the receptor. Furthermore, I show that this activity is 
maintained when the receptor is retained in the ER via a novel point mutation that we describe. 
Importantly, this ER-retained mutant EGFR exhibits constitutive auto-phosphorylation in the 
absence of ligand binding and is capable of inducing cellular transformation by preferentially 
signaling through PI3K and mTOR. In addition, I show that the highly oncogenic mutant 
EGFRvIII is wholly retained in the ER of U87 glioblastoma cells and is robustly phosphorylated 
at this intracellular membrane, demonstrating that this EGFR deletion mutant, implicated in 
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human brain cancers, can be oncogenic in an intracellular location. Taken together, these 
findings provide strong evidence that constitutively active EGFRs are capable of sending 
transforming signals from the ER. 
In Chapter 3, I further explore the range of ways that phospholipids can regulate protein 
dynamics, in this case, in terms of proper biosynthetic trafficking. The described results support 
the notion that a pool of PI4P synthesized by PI4KIIIα is functionally required for proper ER-to-
Golgi trafficking. Using a novel technique that I designed to monitor biosynthetic trafficking, I 
demonstrate that pharmacological inhibition of PI4KIIIα results in ER-retention of both the 
epidermal growth factor receptor (EGFR) and a GPI-anchored protein. Furthermore, I 
demonstrate that specific inhibition of a Golgi-localized PI 4-kinase does not result in ER-
retention. Finally, I show that depletion of PI4P via overexpression of the PI-phosphatase Sac1 
similarly inhibits protein trafficking to the PM. Taken together, these findings provide evidence 
that a specific pool of PI4P, synthesized by PI4KIIIα, is essential for proper biosynthetic protein 
trafficking. 
In Appendix A, I present very recent data assessing the ligand-induced signaling 
capabilities of EGFR JX mutants localized to the PM.  These receptors do not generate the same 
magnitude of a Ca2+ response as wt EGFR, and I provide evidence that this can be explained by 
decreased activation of downstream signaling partners such as PLCγ-1.  I hypothesize that this 
phenomenon is due to the constitutive signaling of JX mutant receptors and thus the lack of an 
un-phosphorylated pool of downstream signaling partners primed for activation. 
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Chapter 2 
 
Ligand-independent Cell Transformation by an ER-retained EGF 
Receptor Mutant 
 
 
2.1 Abstract 
 
Deregulation of ErbB receptor tyrosine kinases is a hallmark of many human cancers. Conserved 
in the ErbB family is a cluster of basic amino acid residues in the juxtamembrane (JX) region. 
We found that charge-silencing mutagenesis within the JX region of the epidermal growth factor 
receptor (EGFR) results in the generation of a mutant receptor (EGFR R1-6) that spontaneously 
transforms NIH 3T3 cells in a ligand-independent manner. The capacity of EGFR R1-6 to 
mediate ligand-independent transformation is maintained when this mutant is retained in the 
endoplasmic reticulum (ER) via a single point mutation, L417H, which we describe. We show 
that EGFR R1-6 with L417H exhibits basal tyrosine phosphorylation when ectopically 
expressed, and its transforming activity is both sensitive to inhibition of EGFR kinase activity 
and particularly dependent on PI3-kinase and mTOR activity. We also evaluate EGFR variant 
type III (EGFRvIII), which is a constitutively active, highly oncogenic mutant form of EGFR 
that has been linked to human brain cancers, although how it transforms cells has not been 
clearly defined. We show that, similar to EGFR R1-6/L417H, EGFRvIII confers transforming 
activity while it is wholly ER-retained in U87 cells. These findings demonstrate that ER-
localized EGFR mutants are capable of potent transforming activity. 
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2.2 Introduction 
 
Receptor tyrosine kinases (RTKs) initiate some of the most complex signaling networks 
in cells (Lemmon and Schlessinger, 2010). To maintain normal cellular homeostasis, RTK 
signaling must be tightly regulated. Loss or perturbation of this regulation leads to defects in 
cellular processes that give rise to oncogenic transformation (Blume-Jensen and Hunter, 2001). 
Oncogenic mutations in RTKs can lead to their over-expression, constitutive activation, and/or 
mislocalization in cells. 
The ErbB family and, in particular, ErbB1, or the epidermal growth factor receptor 
(EGFR), serves as a prototypic model for RTK signaling. EGFR is a Type I transmembrane 
glycoprotein consisting of an extracellular ligand-binding segment, a single transmembrane 
segment, and an intracellular segment that contains a JX region, a tyrosine kinase domain 
(TKD), and a C-terminal tail. Signaling by EGFR is initiated following its ligand-induced 
dimerization, which leads to TKD-dependent phosphorylation of the C-terminal segments of two 
interacting receptors (Schlessinger, 2000). The ~37-residue JX region of EGFR has emerged as a 
key regulator of receptor function (Red Brewer et al., 2009; Jura et al., 2009; Arkhipov et al., 
2013). Several intrinsic sorting signals have been mapped to this JX region (Morrison et al., 
1996; He et al., 2002; Hsu and Hung, 2007), which also contains a basic calmodulin-binding 
sequence (Martin-Nieto and Villaobo, 1998) that additionally interacts with acidic phospholipids 
(McLaughlin et al., 2005; Sengupta et al., 2009; Michailidis et al., 2011). In an active receptor 
dimer, the C-terminal halves of the JX region have been shown to clasp two interacting EGFRs 
together in a conformation that promotes their activation (Red Brewer et al., 2009; Jura et al., 
2009), whereas the N-terminal halves of these domains stabilize this interaction via the formation 
of an antiparallel helical dimer (Jura et al., 2009). Recent evidence suggests that basic residues in 
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the N-terminal JX region facilitate insertion of adjacent hydrophobic amino acid side chains into 
the plasma membrane (PM) bilayer in inactive EGFR, and these leucine side chains are expelled 
during formation of the helical dimer in the active state (Arkhipov et al, 2013, Endres et al., 
2013). 
EGFR plays important roles in cell differentiation, proliferation, and epithelial 
organogenesis (Carpenter, 2000). Changes in its expression and regulation, due to gene 
duplication events (Xu et al., 1984; Libermann et al., 1985; King et al., 1985; Kraus et al., 1987), 
in-frame deletions (Humphrey et al., 1988; Lynch et al., 2004), and point mutations (Lynch et al., 
2004; Red Brewer et al., 2009) have been linked to tumor progression. EGFRvIII (for EGFR 
variant type III) is an example of an in-frame deletion of EGFR found frequently in glioblastoma 
multiforme (GBM), as well as in non-small cell lung carcinomas, breast, and ovarian cancers. 
Expression of this tumor-specific mutant receptor occurs in one-third of GBMs and is an 
independent negative prognostic indicator of survival (Heimberger et al., 2005). It results from 
deletion of exons 2-7 of EGFR (801 bp), which encompasses much of the ligand-binding 
domain. This mutant exhibits constitutive phosphorylation (Huang et al., 1997) and downstream 
signaling through the PI3K pathway (Moscatello et al., 1998) to JNK (Antonyak et al., 1998). 
While it has been reported that EGFRvIII is completely (Eckstrand et al., 1995) or partially 
(Gupta et al., 2010) mislocalized intracellularly, this remains an area of controversy (Wikstrand 
et al., 1997; Johns et al., 2005; Cvrljevic et al., 2011).  The critical question we address in the 
present study is whether a constitutively active variant EGFR that is fully retained in the ER can 
cause cellular transformation. 
Motivated by the hypothesis that electrostatic binding of the polybasic JX region of 
EGFR to acidic phospholipids restricts access of the kinase domain to substrate tyrosines, we 
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demonstrate that reduction of the net charge in the JX region of wild-type (wt) EGFR results in 
constitutive activation of the receptor. Furthermore, we show that this activity is maintained 
when the receptor is retained in the ER via a novel point mutation that we describe. Importantly, 
we find that this ER-retained mutant EGFR exhibits constitutive auto-phosphorylation in the 
absence of ligand binding and is capable of inducing cellular transformation by preferentially 
signaling through PI3K and mTOR. In addition, we show that the highly oncogenic mutant 
EGFRvIII is wholly retained in the ER of U87 glioblastoma cells and is robustly phosphorylated 
at this intracellular membrane, demonstrating that this EGFR deletion mutant, implicated in 
human brain cancers, can be oncogenic in an intracellular location. Taken together, these 
findings provide strong evidence that constitutively active EGFRs are capable of sending 
transforming signals from the ER. 
 
2.3 Materials and Methods 
 
2.3.1 Materials 
 All cell culture reagents, EGF, and precast gels for blotting were from Invitrogen. 
FuGene HD was from Roche Applied Sciences. The anti-N-terminal (clone LA1) and anti-C-
terminal (clone E235) human EGFR antibodies (used for immunochemistry), as well as the 
PVDF filters, were from Millipore Corp. The anti-PDI mAb was from Affinity Bioreagents. All 
Alexa dye-conjugated secondary antibodies were from Invitrogen, and the Cy5-conjugated anti-
rabbit IgG was from Jackson ImmunoResearch Laboratories. The antibodies that recognize the 
phosphorylated forms of Akt and Erk, as well as phospho-specific EGFR antibody (1068), the 
anti-EGFR (used for blotting), and anti-phosphotyrosine antibodies were from Cell Signaling. 
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The anti-actin antibody was from LabVision/Thermo. HRP-conjugated secondary antibodies 
used for blotting were from GE Healthcare. LY294002, PD98059, and rapamycin were from 
EMDBiosciences. Gefitinib (Iressa) was from Selleck Chemicals. The Endo H and PNGase F, as 
well as restriction enzymes (DpnI, XbaI, EcoRI, MfeI), and the Phusion High-Fidelity DNA 
Polymerase were from New England Biolabs. The anti-GFP mAb, monoclonal anti-EGFR (clone 
225, Cetuximab), as well as any chemical not noted otherwise were purchased from Sigma-
Aldrich Chemical Co.  
2.3.2 Expression Plasmids 
 The human EGFR-GFP construct has been described previously (Monick et al., 2005). 
To generate the juxtamembrane mutants, site-directed mutagenesis was performed using the 
QuikChange site-directed mutagenesis kit (Stratagene) or Phusion High-Fidelity DNA 
Polymerase (New England BioLabs). Amino acid numbering includes the 24-residue membrane-
targeting signal sequence. Prior to the generation of stable cell lines, the wt and mutant EGFR 
constructs were cloned into the pKH3 expression vector (Addgene) using the Xba1 and EcoR1 
restriction sites. Primers containing the XbaI and MfeI restriction sites were annealed to the N 
and C-termini, respectively, of EGFR constructs, due to the presence of an EcoRI restriction site 
within EGFR. The particular restriction sites were chosen to eliminate the triple-HA tag, present 
in the pkH3 vector, from the final protein product. EGFR-vIII cDNA was obtained in an MSCV-
XZ066 vector (Addgene). The EGFR-vIII-pkH3 construct was made as described above for the 
other EGFR-constructs.  
2.3.3 Cell Culture 
Rat RBL-2H3 mast cells were grown in MEM containing 20% (v/v) fetal bovine serum 
(FBS) (Atlanta Biologicals) and 10 µg/ml gentamicin sulfate as described previously (Gosse, 
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2005). In preparation for imaging and flow cytometry, cells were plated at 25-50% confluency 
into 35 mm MatTek wells (MatTek Corporation) or 60 mm dishes, respectively. After 
approximately 20 h, RBL-2H3 cells were transfected with either mutant or wild-type versions of 
EGFR. These constructs were transfected using Fugene HD (Roche) per manufacturers’ 
instructions, with modification to enhance transfection efficiency in the RBL cells previously 
described (Gosse et al., 2005). Cells were processed for imaging or flow cytometry 24 h after 
transfection. 
Human HeLa cells were grown in RPMI containing 10% FBS. Mouse NIH 3T3 cells 
were grown in DMEM containing 10% (v/v) calf serum (CS). In preparation for imaging, cells 
were plated at 50% confluency into 35 mm MatTek wells. After approximately 20 h, cells were 
transfected with either mutant or wild-type versions of EGFR. These constructs were transfected 
using Fugene HD (Roche) per manufacturers’ instructions. U87 cells were grown in DMEM 
supplemented with 10% (v/v) FBS. Where indicated, NIH 3T3 or U87 cells were treated with 0.1 
µg/ml or 0.02 µg/ml EGF. To generate stable cell lines, NIH 3T3 or U87 cells were transfected 
with the various pkH3 vectors, either alone or incorporating EGFR constructs, using FuGene HD 
(Roche). Transfected cells were maintained in DMEM supplemented with 10% CS (NIH 3T3) or 
10% FBS (U87) and 2 µg/ml puromycin (Invitrogen). After 10–14 days, puromycin-resistant 
colonies were selected (NIH 3T3) or pooled (U87) and subcultured in DMEM supplemented 
with 10% CS (NIH 3T3) or 10% FBS (U87) and 0.5 µg/ml puromycin. The clones/lines were 
then assessed for expression of each respective EGFR construct. 
2.3.4 Confocal Fluorescence Microscopy 
 NIH 3T3 and RBL-2H3 cells were washed once with BSS (BSS: 20 mM HEPES, 135 
mM NaCl, 1.8 mM CaCl2, 2 mM MgCl2, 5.6 mM glucose, 1 mg/ml BSA, pH 7.4), fixed using 
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4% paraformaldehyde with 0.1% glutaraldehyde, permeabilized (or not) with either 1% v/v 
Triton X-100 or 0.05% w/v saponin, and labeled for 1 hour with specified antibodies in 
phosphate buffered saline (PBS) with 10 mg/ml BSA and 0.01% w/v sodium azide (PBS/BSA). 
Images were collected using an upright Leica TCS SP2 laser scanning confocal microscope 
(Leica Microsystems, Exton, PA) with a 63 x 0.9 NA, HCX APO L U-V-I water-immersion 
objective. 
2.3.5 Flow Cytometry  
 RBL-2H3 cells were harvested, washed once with BSS, fixed using 4% 
paraformaldehyde with 0.1% glutaraldehyde, and washed once with PBS/BSA. Cells expressing 
GFP-tagged wild-type or mutant EGFR constructs were labeled with appropriate antibodies for 1 
h in PBS/BSA. Samples were evaluated using a Becton Dickinson LSR II flow cytometer, and 
data were analyzed using BD FACSDiva software. Analysis was gated to include single cells on 
the basis of forward and side light-scatter and data from single-color samples were used to 
determine the gates for positive fluorescence from each fluorophore.  
2.3.6 Immunoblot Analysis 
Cells were washed in PBS, incubated in lysis buffer (25mM Tris, pH7.4, 100mM NaCl, 
1mM EDTA, 1% (v/v) Triton 100, 1mM DTT, 1mΜ sodium orthovanadate, 1mM β-glycerol 
phosphate, 1µg/mL leupeptin, and 1µg/mL aprotinin), and supernatants were retained following 
microfuge centrifugation. Protein concentrations of the whole-cell lysates (WCL) were 
determined using the Bio-Rad DC protein assay. The WCL (35 µg/lane) were resolved by 
SDS/PAGE, and the proteins were transferred to PVDF membranes. The filters were blocked in 
10% BSA diluted in 20 mM Tris, 135 mM NaCl, and 0.02% Tween 20 and then incubated with 
the indicated primary antibodies diluted in the same buffer. The primary antibodies were 
 
40 
 
detected with HRP-conjugated secondary antibodies followed by exposure to ECL reagent 
(Invitrogen).  
2.3.7 Endo H Sensitivity Assay  
NIH 3T3 or U87 cells were lysed as above, and WCLs were divided into three equal 
portions, which then were not treated or treated with endoglycosidase H (Endo H) (Maley et al., 
1989) or peptide: N-glycosidase F (PNGase F) according to the manufacturer's instructions (New 
England Biolabs). Samples were incubated for 24 hours at 37°C, and the digestion reactions 
were stopped by boiling at 95°C for 5 min after the addition of SDS-PAGE sample buffer. 
Samples were analyzed by immunoblotting. 
2.3.8 Anchorage-independent Growth Assays 
NIH 3T3 cells stably overexpressing vector only (control), wt EGFR, EGFR Mut R1-5, 
EGFR Mut R1-6, EGFR L417H, or EGFR R1-6/L417H were plated at densities of 8.5 x 103 
cells/ml in medium containing 0.3% agarose, with or without EGF or specified inhibitors, onto 
underlays composed of growth medium containing 0.6% agarose in six-well dishes. The soft 
agar cultures were re-fed with fresh medium (including EGF or specified inhibitors) every fifth 
day for 15-20 days, at which time the colonies that had formed were counted. Each of the assays 
was performed at least three times, and the results were averaged and expressed +/- SD. 
Experiments using parental U87 cells and cells stably expressing EGFRvIII were performed 
similarly except 3 x103 cell/ml were plated in medium containing 0.3% agarose and colonies 
were enumerated after 6 days, including re-feeding with fresh medium inhibitor on day 3.  
2.3.9 Data Analysis 
Statistical analyses were determined using GraphPad Prism (GraphPad Software, La 
Jolla, CA), using the Student t test, with p ≤ 0.05 considered statistically significant.  
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2.4 Results 
2.4.1 A single point mutation within the N-terminal domain of EGFR prevents its 
trafficking to the plasma membrane. 
In an effort to investigate the potential roles of basic JX residues in receptor-mediated 
cell signaling, we focused on the polybasic JX region (Figure 1A) of EGFR (Aifa et al., 2006; 
Sato et al., 2006; Jura et al., 2009; Theil and Carpenter, 2007).  Based on the work of others 
(McLaughlin et al., 2005; Sengupta et al., 2009), we hypothesized that charge silencing within 
the JX sequence of EGFR would release regulatory electrostatic interactions with membrane 
lipids and thereby promote the activity of the TKD (see Discussion). We sequentially mutated 
basic residues in this sequence to alanines within a C-terminal GFP-tagged EGFR (Figure 2.1A). 
Whereas wt EGFR-GFP is found almost exclusively at the PM when expressed in RBL mast 
cells, reduction in the net charge of the JX region from +8 to +3 (EGFR Mut R1-6) initially 
appeared to result in complete intracellular retention.  However, sequencing revealed that 
unintentional mutagenesis occurred during the design of Mut R1-6, and that a single point 
mutation, L417H, in the EGFR extracellular domain is responsible for the trafficking defect 
(EGFR Mut R1-6/L417H). When this single point mutation was made in the context of wt EGFR 
(wt EGFR L417H), trafficking was similarly prevented, as evidenced by both confocal imaging 
(Figure 2.1B) and quantitative flow cytometry (Figure 2.1C). 
   
 
 
 
 
 
42 
 
 
 
 
 
 
Figure 2.1. A single point mutation L417H within the N-terminal segment of EGFR inhibits its 
capacity to traffic to the plasma membrane. (A) Wild-type and mutant EGFR-GFP constructs. 
The JX sequence in EGFR is shown, with basic amino acids in bold and mutated residues 
underlined. (TM = transmembrane) (B) Expression of wt and mutant EGFR-GFP constructs in 
suspended RBL mast cells. Transiently-expressing cells were fixed and labeled with an anti-N-
terminal EGFR antibody, followed by Alexa647-anti-IgG. (C) Quantification of the effect of 
mutation of the polybasic JX segment of EGFR and the L417H point mutation (LH) on 
biosynthetic trafficking. RBL-2H3 cells transiently expressing GFP-tagged EGFR constructs 
were harvested, fixed and labeled with anti-N-terminal EGFR antibody followed by Alexa647-
anti-IgG, then analyzed by flow cytometry to determine the ratio of PM-localized EGFR 
fluorescence to total-EGFR fluorescence. Data from mutants are normalized to wt and error bars 
indicate ± SD of three independent experiments in which >8,000 cells expressing each construct 
were analyzed.  
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Figure 2.2. EGFR-GFP Mut R1-6/L417H is retained and intact within the ER. (A) Attached 
RBL mast cells transiently expressing wt EGFR-GFP, EGFR-GFP Mut R1-6, EGFR-GFP 
L417H, or EGFR-GFP Mut R1-6/L417H were fixed, permeabilized, and labeled with an anti-
PDI antibody followed by Alexa555-anti-mouse IgG to label the ER. (B) Whole cell lysates from 
RBL mast cells transiently expressing either wt EGFR, EGFR Mut R1-6, or EGFR Mut R1-
6/L417H were untreated (Un), treated with Endo H (EH), or treated with PNGase F (PNG) for 24 
hours before Western blot analysis with an anti-EGFR antibody. (C) Whole cell lysates of either 
RBL-2H3 or HeLa cells untransfected (Un) or transiently expressing either wt EGFR (Wt) or 
EGFR Mut R1-6/L417H (R1-6 LH) were probed with an anti-EGFR antibody. Lower band in 
doublet bands is endogenous EGFR. 
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Strong evidence that EGFR L417H and EGFR Mut R1-6/L417H localize to the ER is 
provided by immunofluorescent colocalization with the resident lumenal ER protein, PDI (Figure 
2.2A), and by complete sensitivity of EGFR MutR1-6/L417H to digestion by endoglycosidase H 
(Endo H; Figure 2.2B). The Endo H sensitive band is the same molecular weight as the Peptide-
N-Glycosidase F (PNGase F)-sensitive band. PNGase F removes all glycosylations, and serves 
as a control for these assays. In contrast, wt EGFR and EGFR Mut R1-6 show only a small 
amount of Endo H sensitivity, consistent with confocal imaging and flow cytometry results 
showing predominant surface localization for both of these proteins (Figure 2.1). Immunoblot 
analysis shows that EGFR Mut R1-6/L417H retained in the ER is intact both in RBL-2H3 cells, 
which do not endogenously express EGFR, and in HeLa cells, which have high levels of 
endogenous EGFR (Figure 2.2C). ER-retained EGFR Mut R1-6/L417H appears to be oriented 
correctly across the ER membrane, with its C-terminal domain extending into the cytosol: 
Confocal imaging of cells in which the PM (but not the ER) was selectively permeabilized with a 
low concentration of saponin showed that these receptors are labeled with anti-GFP antibody 
(Figure 2.3). Collectively, these results show that EGFR Mut R1-6/L417H is confined to the ER, 
whereas EGFR Mut R1-6 is largely expressed at the PM. 
 
2.4.2 ER-retained EGFR Mut R1-6/L417H transforms cells independently of EGF.  
We hypothesized that charge silencing within the JX sequence of EGFR would release 
regulatory electrostatic interactions with acidic phospholipids and thereby promote the activity of 
the TKD.  Thus, we tested the possibility that EGFR Mut R1-6 would promote cell 
transformation due to constitutive activation by generating NIH 3T3 cell lines stably over- 
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Figure 2.3. EGFR-GFP Mut R1-6/L417H is correctly oriented across the ER membrane. (A) 
The lumen of the ER, marked by PDI, is accessed when 1% TX-100 is used as a 
permeabilization agent, but not with 0.05% saponin, which permeabilizes the PM without 
permeabilizing internal membranes. RBL-2H3 cells were fixed, permeabilized as indicated, and 
labeled with an anti-PDI mAb followed by Alexa 555-anti-mouse IgG. (B) RBL-2H3 cells 
transiently expressing wt EGFR-GFP or EGFR-GFP Mut R1-6/L417H were fixed, permeabilized 
as indicated and labeled with anti-GFP mAb followed by Alexa555-anti-mouse IgG to label the 
C-terminus of the expressed EGFR construct. The GFP epitope on the EGFR-GFP Mut R1-
6/L417H C-terminus is labeled following permeabilization with either 0.05% saponin or TX-
100, consistent with cytoplasmic exposure. 
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expressing wt EGFR, EGFR Mut R1-5, EGFR Mut R1-6, EGFR L417H, and EGFR Mut R1-
6/L417H and comparing their anchorage-independent growth. We selected a NIH 3T3 sub-line 
that has an unusually low expression of endogenous EGFR (Wikstrand et al., 1995), and the 
EGFR constructs we used for stable expression contained no GFP tag. 
Selected clones stably expressing wt EGFR, EGFR Mut R1-5, and EGFR Mut R1-6, were 
found to express their respective EGFR proteins to similar extents, while levels of ER-retained 
EGFR L417H and EGFR Mut R1-6/L417H are somewhat lower (Figure 2.4A). However, in all 
five cases, robust over-expression of EGFR was observed to be far above the endogenous level 
of EGFR expressed by the parent NIH 3T3 cell line (vector control; Figure 2.4A), and cellular  
distributions are similar to those proteins transiently expressed in RBL-2H3 cells (compare Figs. 
2.1B and 2.4B). Endo H sensitivity further shows that these stably expressed EGFR proteins 
localize in NIH 3T3 cells similarly to their transiently expressed counterparts in RBL-2H3 cells: 
wt EGFR and EGFR Mut R1-6 are largely trafficked out of the ER, whereas EGFR mutants that 
contain L417H are localized exclusively in the ER (compare Figure 2.4C to Figure 2.2B).  
 We tested the stably expressed receptors for their capacity to induce anchorage 
independent growth, a reliable indicator of transformation (Macpherson and Montagnier, 1964). 
Although the NIH 3T3 cells stably expressing vector alone exhibit small amounts of endogenous 
EGFR, these levels are not sufficient to mediate anchorage-independent growth, even when 
stimulated with EGF. Overexpression of wt EGFR results in robust transformation, but only in 
the presence of EGF (Figure 2.5 A and B). Similarly, over-expressed EGFR Mut R1-5 transforms 
NIH 3T3 cells in an EGF-dependent manner. However, stably expressed EGFR Mut R1-6 
stimulates the anchorage independent growth of NIH 3T3 cells even in the absence of EGF. 
Furthermore, EGFR Mut R1-6/L417H retains the capacity to transform cells in a ligand-  
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Figure 2.4. EGFR Mut R1-6/L417H is retained in the ER when stably expressed in NIH 3T3 
cells. (A) Whole cell lysates of NIH 3T3 cells stably expressing wt EGFR, EGFR Mut R1-5, 
EGFR Mut R1-6, EGFR L417H, EGFR Mut R1-6/L417H, or vector only were subjected to 
Western blot analysis using an anti- EGFR antibody and an anti-actin antibody (loading control). 
(B) Confocal images of NIH 3T3 cells stably expressing vector only, wt EGFR, EGFR Mut R1-
6, EGFR L417H, or EGFR Mut R1-6/L417H. Prior to imaging, cells were fixed and labeled with 
an anti-N-terminal EGFR antibody followed by Alexa 647 anti-mouse IgG, then washed, 
permeabilized, and labeled with anti-C-terminal EGFR antibody followed by Alexa 488-anti-
rabbit IgG. (C) Whole cell lysates from NIH 3T3 cells stably expressing either the wt EGFR, 
EGFR Mut R1-6, EGFR Mut R1-6/L417H, or EGFR L417H were untreated, or were treated with 
Endo H or with PNGase F for 24 hours before Western blot analysis with an anti-EGFR 
antibody.  
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Figure 2.5. ER-retained EGFR MutR1-6/L417H transforms cells in a growth factor-independent 
manner. (A) NIH 3T3 fibroblasts stably expressing vector, wt EGFR, EGFR Mut R1-5, EGFR 
Mut R1-6, EGFR L417H, or EGFR Mut R1-6/L417H, incubated with or without EGF (100 
ng/ml), were cultured in soft agar. The data shown represent the mean ± SD for colonies per 2.25 
cm2 from at least three independent experiments. ***, P<0.001. (B) Representative images of the 
colonies quantified in A. (C) Three different clones of NIH 3T3 fibroblasts stably expressing 
EGFR Mut R1-6/L417H cultured in soft agar as in A (Mean ± SD from three independent 
experiments). Western blot analysis using an anti-EGFR antibody was performed on whole cell 
lysates from the same three clones and vector control cells, without or with EGF stimulation to 
determine relative expression levels. 
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independent manner, whereas EGFR L417H is incapable of transforming NIH 3T3 fibroblasts in 
the absence or presence of ligand. The transforming capacity of EGFR Mut R1-6/L417H is 
observed in multiple clones, and the degree of colony formation by these clones correlates with 
EGFR Mut R1-6/L417H expression levels (Figure 2.5C). Likewise, EGFR Mut R1-6, which 
expresses to a higher level than EGFR Mut R1-6/L417H (Figure 2.4A), forms more colonies than 
this ER-retained mutant in soft agar in the presence and absence of EGF (Figs. 2.5A and B). 
Collectively, these results show that the charge silencing mutation R1-6 in the JX region leads to 
structural alterations in EGFR that cause ligand-independent transformation by receptors at the 
PM and the ER. 
We observe that EGF consistently enhances the number of colonies formed in NIH 3T3 
cells stably expressing EGFR Mut R1-6/L417H by a small, but statistically significant, amount 
(Figure 2.5A). Thus, we tested the possibility that a small population of EGFR Mut R1-6/L417H, 
below the level of detection by imaging (Figure 2.4B) and Endo H sensitivity assays (Figure 
2.4C), is trafficked to the PM. Anchorage independent growth assays were carried out on the 
cells expressing EGFR Mut R1-6/L417H in the presence of the anti-EGFR antibody Cetuximab 
(mAb 225), which prevents the transition of EGFR to its active conformation (Li et al., 2005). 
Ligand-independent transformation mediated by EGFR Mut R1-6/L417H that is due to a PM-
associated pool would be expected to be reduced in the presence of this antibody. However, 
addition of Cetuximab did not decrease transformation mediated by EGFR Mut R1-6/L417H 
under conditions in which it significantly inhibited transformation by wt EGFR (Figure 2.6). 
These findings suggest that the enhanced transformation seen in NIH 3T3 cells stably expressing 
the EGFR Mut R1-6/L417H in the presence of EGF is due to signaling by endogenous EGFR at  
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Figure 2.6. Anti-EGFR Cetuximab does not inhibit transformation by EGFR Mut R1-6/L417H. 
NIH 3T3 cells stably expressing wt EGFR or EGFR Mut R1-6/L417H were cultured in soft agar 
in the presence or absence of Cetuximab (5 µg/ml) and / or EGF (20 ng/ml). Mean ± SD from 
three independent experiments, **, P<0.01; n.s., not significant.  
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the PM that synergizes with activity of constitutively active EGFR Mut R1-6/L417H at the ER 
(see Discussion). 
 
2.4.3 Transformation mediated by ER-retained EGFR Mut R1-6/L417H requires its kinase 
activity.  
We investigated whether EGFR Mut R1-6/L417H signals to cytoplasmic proteins to 
transform cells. We found that treatment with the EGFR tyrosine kinase inhibitor, gefitinib 
(Iressa) at 2.5 µM eliminates transformation mediated both by NIH 3T3 cells expressing EGFR 
Mut R1-6/L417H and by EGF-stimulated NIH 3T3 cells overexpressing wt EGFR (Figure 2.7A). 
The effects of gefitinib on both of these stable cell lines is dose-dependent, with IC50 values of < 
2 µΜ gefitinib (data not shown). We also observed significant basal phosphorylation of EGFR 
Mut R1-6/L417H by Western blotting of whole cell lysates from cells expressing this mutant 
receptor using anti-phospho-EGFR (Y1068) antibody.  This phosphorylation is not detectably 
enhanced upon EGF addition, and decreases substantially upon treatment with gefitinib (Figure 
2.7B). These results suggest that the ligand-independent transformation mediated by the ER-
retained EGFR Mut R1-6/L417H is consistent with its constitutive activity. Wt EGFR (and 
EGFR L417H) exhibits a lower level of constitutive phosphorylation at residue 1068, and Endo 
H digestion analysis confirms that the wt EGFR that becomes robustly phosphorylated at Y1068 
upon the addition of ligand is not in the ER, but rather is located at the PM (Figure 2.7C). In 
contrast, Y1068-phosphorylated EGFR Mut R1-6/L417H is retained in the ER (Figure 2.7C), 
providing additional evidence that receptor signaling from this location leads to transformation.  
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Fig. 2.7. Transformation by ER-retained EGFR Mut R1-6/L417H and its ligand-independent 
phosphorylation are EGFR kinase-dependent. (A) Inhibition of colony formation of NIH 3T3 
clones by the EGFR kinase inhibitor gefitinib (2.5 µM). Data shown are the mean ± SD from 
three independent experiments. ***, P<0.001; ****, P<0.0001. (B) Quantification of phospho-
Y1068 EGFR detected in the whole cell lysates from serum starved NIH 3T3 cells expressing 
EGFR Mut R1-6/L417H, treated as shown (gefitinib = 5 µM). Data were averaged from four 
independent experiments. Error bars show S.E., **, P<0.01, n.s., not significant. (C) Whole cell 
lysates from serum-starved NIH 3T3 cells stably expressing either wt EGFR, EGFR Mut R1-6, 
or EGFR Mut R1-6/L417H were treated without or with EGF as in Fig. 3. Lysates (equal protein 
content) were untreated or were treated with Endo H, or with PNGase F for 24 hours before 
Western blot analysis using anti-phospho-Y1068-EGFR and anti-actin antibodies. 
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2.4.4 The ER-retained EGFR Mut R1-6/L417H signals through the PI3K pathway.  
To determine the signaling pathway(s) responsible for mediating the ligand-independent 
transforming activity of EGFR Mut R1-6/L417H, we focused our investigation on proteins that 
interact with EGFR via phospho-Y1068, including PI3K. Figure 2.8 summarizes results 
comparing the activity of this pathway in the NIH3 3T3 cells stably expressing wt EGFR to those 
expressing EGFR Mut R1-6/L417H. Cells expressing EGFR Mut R1-6/L417H exhibit higher 
basal levels (without EGF stimulation) of activated Akt than cells expressing wt EGFR (Figure 
2.8 A and B), and this activation is prevented by treatment with the PI3K inhibitor LY294002 at 
10 µM (Figure 2.8A). Furthermore, treatment with a concentration of LY294002 (5 µM) that 
only partially decreases EGF-dependent wt EGFR-mediated anchorage-independent cell growth 
abolishes colony formation mediated by EGFR Mut R1-6/L417H, suggesting greater sensitivity 
of transformation by this mutant to PI3-kinase inhibition (Figure 2.8C). Similarly, transformation 
mediated by EGFR Mut R1-6/L417H is more susceptible to rapamycin, an inhibitor that 
interferes with the capacity of PI3K to signal through mTOR, than transformation mediated by 
wt EGFR (Figure 2.8D). In contrast, cells expressing EGFR Mut R1-6/L417H do not show 
elevated levels of phosphorylated Erk compared to wt EGFR-expressing and vector control cells, 
with or without EGF stimulation, and treatment with the MEK inhibitor PD98059 inhibits 
transformation mediated by wt EGFR and EGFR Mut R1-6/L417H to a similar extent (Figure 
2.9). These results provide a consistent picture that the transformation caused by ER-retained 
EGFR Mut R1-6/L417H is mediated primarily by the PI3K-mTOR signaling axis. 
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Figure 2.8. Transformation mediated by ER-retained EGFR Mut R1-6/L417H depends on PI3K 
signaling. (A) Whole cell lysates from serum-starved NIH 3T3 cells stably expressing wt EGFR 
or EGFR Mut R1-6/L417H and treated as indicated were immunoblotted with antibodies specific 
for phospho-Akt S473, total EGFR, or actin (loading control). Before lysing the cells, EGF was 
added for 5 min at 100 ng/ml in the presence or absence of 10 µM LY294002 (LY). (B) 
Quantification of Akt phosphorylation in cells expressing wt EGFR or EGFR Mut R1-6/L417H 
in the absence of EGF. Data averaged from five independent experiments including that shown 
in A (error bars show S.E., **, P<0.01). (C) The effect of the PI3K inhibitor LY294002 (5µM) 
on the capacity of wt EGFR or EGFR Mut R1-6/L417H-expressing cells to grow in soft agar. 
The data shown represent the mean ± SD from three independent experiments. *, P<0.05; ****, 
P<0.0001. (D) The effect of mTOR inhibition on the capacity of wt EGFR or EGFR Mut R1-
6/L417H-expressing cells to grow in soft agar was assessed by adding rapamycin (25 nM) to soft 
agar cultures. Mean ± SD from three independent experiments, **, P<0.01; ****, P<0.0001. 
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Figure 2.9. Contribution of Erk pathway to EGFR Mut R1-6/L417H-mediated transformation. 
(A) Whole cell lysates of serum-starved NIH 3T3 cells stably expressing vector control, wt 
EGFR, or EGFR Mut R1-6/L417H were treated or not with EGF (100 ng/ml) and or gefitinib 
(5µM) and immunoblotted with antibodies against phospho-Erk, total EGFR, and actin (loading 
control). (B) Inhibition of transformation by the MEK inhibitor PD98059 (50 µM). Mean ± SD 
from three independent experiments, ***, P<0.001; ****, P<0.0001. 
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2.4.5 EGFRvIII localizes to the ER where it is constitutively active in U87 cells.  
Because the subcellular distribution of EGFRvIII in cancer cells has been controversial, 
we investigated this question by generating U87 human glioblastoma cells that stably express 
EGFRvIII. Similar to EGFR Mut R1-6/L417H in NIH 3T3 cells, we found that EGFRvIII in U87 
cells is robustly phosphorylated on tyrosine 1068 (Y1068), independent of EGF, and that Akt 
and c-Jun, components of the PI3K signaling pathway, are also basally phosphorylated (Figure 
2.10A). U87 cells expressing EGFRvIII show enhanced transformation compared to vector 
control, as revealed by anchorage independent growth assays in soft agar, and this colony 
formation is inhibited by treatment with gefitinib (Figure 2.10B). Immunochemical labeling of 
EGFRvIII with an antibody specific for the cytoplasmic C-terminus of EGFR showed a clear 
reticulate pattern that colocalizes with PDI (Figure 2.10C). ER-localization of EGFRvIII in U87 
cells was further confirmed by complete sensitivity of this mutant receptor to digestion by Endo 
H (Figure 2.10D). Furthermore, Y1068-phosphorylated EGFRvIII is Endo H sensitive, 
corresponding to ER localization, whereas Y1068-phosphorylated wt EGFR is not, consistent 
with PM localization of this receptor (Figure 2.10D). These results demonstrate that EGFRvIII, 
like EGFR R1-6/L417H, can signal from the ER in a ligand-independent manner.  
 
2.5 Discussion   
The concept of signal generation from phosphorylated RTKs that are activated by their 
respective ligands at the PM has been a tenet in the field of receptor biology since the early 
1980’s (Ushiro and Cohen, 1980). The findings that many epithelial tumors overexpress RTKs, 
particularly members of the ErbB family, and that they are key contributors in cancer  
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Figure 2.10. EGFRvIII stably expressed in U87 glioblastoma cells is robustly phosphorylated, 
enhances cell transformation, and is localized to the ER. (A) Parental U87 cells and those stably 
expressing EGFRvIII were treated without or with 100 ng/ml EGF for 5 min. Whole cell lysates 
were electrophoresed and Western blots were probed with antibodies that recognize EGFR, or 
the activated forms of EGFR (phospho-Y1068-EGFR), Akt (P-T308) and c-Jun. (B) Parental 
U87 cells and those stably expressing EGFRvIII were cultured in soft agar without EGF, with or 
without gefitinib (20 µM). The data shown represent the mean ± SD for colonies per 2.25 cm2 
from at least three independent experiments. ***, P<0.001; ****, P<0.0001. (C) Parental U87 
cells and those stably expressing EGFRvIII were fixed, permeabilized, and labeled with an anti-
C-terminal EGFR antibody followed by Alexa 488-anti-rabbit IgG. Cells were then labeled with 
an anti-PDI antibody followed by Alexa555-anti-mouse IgG to label the ER. (D) Whole cell 
lysates from parental U87 cells and those stably expressing EGFRvIII treated without or with 
EGF (100 ng/ml) were untreated (Un) or treated with Endo H (EH) or with PNGase F (PNG) for 
24 hours before Western blot analysis using an anti-EGFR antibody or an anti-phospho-Y1068-
EGFR antibody.  
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progression (Clark et al., 1984), led to an explosion of a field that continues to grow at a rapid 
pace today. By the end of that decade it was understood that, like overexpression, mutations in 
RTKs can lead to dysregulated signaling. A prominent example in human brain cancers is 
EGFRvIII, a deletion mutant lacking exons 2-7 (Humphrey et al., 1988). While a number of 
other cancer-causing mutations within surface-localized RTKs have been described previously 
(Lemmon and Schlessinger, 2010), impaired receptor trafficking both to and from the PM has 
been recognized more recently as yet another possible mechanism of dysregulation (Choudhary 
et al., 2009; Carpenter and Liao, 2009).  
Prompted by the hypothesis that the basic residues in the JX region of EGFR negatively 
regulate kinase domain interactions, we sequentially mutated these residues to alanines. We 
found that, by reducing the net charge of the polybasic region within the JX region of EGFR 
from +8 to +3, we generated a receptor (EGFR Mut R1-6) that is constitutively active and can 
transform cells even when retained in the ER by a point mutation (L417H; Figs. 2.5 and 2.7). We 
showed that EGFR Mut R1-6/L417H receptors are intracellularly retained using both confocal 
microscopy and quantitative flow cytometry (Figs. 2.1 and 2.4), and we identified the site of 
retention as the ER both by colocalization with the ER-marker PDI (Figure 2.2A) and by Endo H 
digestion (Figs. 2.2B and 2.4C). Similarly, we demonstrate that EGFRvIII in U87 cells is 
completely Endo H sensitive (Figure 2.10D) and that its immunolabeling colocalizes with PDI 
(Figure 2.10C), consistent with its ER localization. Furthermore, we show that both EGFRvIII 
(Figure 2.10) and EGFR Mut R1-6/L417H (see below) are constitutively phosphorylated in the 
ER and signal primarily through the PI3K pathway to mediate cell transformation. 
 Although ER-retained RTK mutants have been described previously (Ekstrand et al., 
1995; Privalsky et al., 1984), these mutants all possess a large deletion of the original protein 
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sequence. Novel to this study is the discovery that a single amino acid substitution of leucine 417 
for histidine results in the retention of EGFR in the ER. The causative factor for retention seems 
to be the loss of leucine 417, as replacement of this residue with alanine also results in complete 
ER-retention, and replacement with a phenylalanine results in dramatically reduced PM 
association (Figure 2.11). Leucine 417 is located in domain III of the extracellular region of 
EGFR, which resembles other leucine-rich repeat proteins (Bajaj et al., 1987; Ward and Garrett, 
2001). We hypothesize that replacement of leucine 417 with a histidine or alanine residue 
disrupts the closely packed hydrophobic core of the leucine-rich repeat, and this disruption 
results in a structural change, which in turn disallows the exit from the ER of EGFRs containing 
this mutation. Interestingly, human ErbB3 and ErbB4 both have a hydrophobic phenylalanine at 
position 417 (Ward and Garrett, 2001), consistent with the observed tolerance for this 
substitution in EGFR. 
 It has been suggested that electrostatic binding of the JX region and a TKD face to acidic 
lipids in the PM may restrict access of the kinase domain to substrate tyrosines in inactive 
conformations (McLaughlin et al., 2005). Recently reported molecular dynamics simulations 
suggest that basic residues in the JX region of EGFR associate electrostatically with acidic lipids 
and can contribute to burying hydrophobic residues of the JX region of inactive EGFRs in the 
membrane (Arkhipov et al., 2013). We hypothesized that an EGFR mutant lacking these basic 
amino acids has a more easily accessible kinase domain that signals without regulation. 
Consistent with this view, we showed that stable expression of EGFR Mut R1-6 confers the 
capacity of NIH 3T3 cells to form colonies under anchorage-independent and ligand-independent 
conditions, irrespective of its localization at the PM or ER (Figure 2.5). Notably, stable 
expression of EGFR Mut R1-5 does not result in ligand-independent transformation, indicating  
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Figure 2.11. EGFR-GFP L417A is ER-retained, whereas EGFR-GFP L417F shows reduced PM 
association. (A) Expression of wt and mutant EGFR-GFP constructs in suspended RBL mast 
cells. Transiently expressing cells were fixed and labeled with an anti-N-terminal EGFR 
antibody, followed by Alexa647-anti-IgG to detect PM-associated EGFR. (B) Quantification of 
the effect of the L417H (LH), L417F (LF), and L417A (LA) point mutations on biosynthetic 
trafficking. RBL-2H3 cells transiently expressing GFP-tagged EGFR constructs were harvested, 
fixed and labeled with anti-N-terminal EGFR antibody followed by Alexa647-anti-IgG, then 
analyzed by flow cytometry to determine the ratio of PM-localized EGFR fluorescence to total-
EGFR fluorescence. Data from mutants is normalized to wt and >8,000 cells expressing each 
construct were analyzed. 
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that reduction of the net charge of the polybasic JX region from +8 to +3 is the minimal change 
necessary for constitutive kinase activity and oncogenic potential of EGFR Mut R1-6. 
Furthermore, this constitutively active mutant maintains its activity and transforming ability 
when retained in the ER (Mut R1-6/L417H; Figure 2.5). We show that this ER-retained EGFR 
Mut R1-6/L417H is phosphorylated at this intracellular location (Figure 2.7C), and the 
extracellular antagonist Cetuximab does not inhibit this ligand-independent transformation 
(Figure 2.6).  Interestingly, the number of colonies formed by EGFR Mut R1-6/L417H-
expressing cells increases to a small but significant extent in the presence of EGF (Figure 2.5A). 
This may be explained by the small amount of EGFR that is endogenous to the parental NIH 3T3 
cells, which is not sufficient to promote colony formation in soft agar in response to EGF, but 
may synergize with the large number of constitutively active Mut R1-6/L417H EGFRs. This 
synergy may involve additional activation of Erk by EGF (Figure 2.9).  
Consistent with a constitutively activated state, EGFR Mut R1-6/L417H is 
phosphorylated at residue Y1068 independent of the addition of EGF (Figure 2.7 B and C). We 
are currently investigating the nature of this constitutive phosphorylated state, including the 
possibility that EGFR Mut R1-6/L417H forms dimers in the ER. Interestingly, two of the 
mutated residues, arginine 651 and lysine 652, are involved in the formation of an antiparallel 
coiled-coil that is predicted to be important for the formation of active dimers (Jura et al., 2009). 
Activation of EGFRvIII has been suggested to be independent of dimer formation (Chu et al., 
1997); thus, understanding the basis for activation of EGFR Mut R1-6/L417H could reveal a 
potentially novel mechanism for EGFR dimerization that could be more generally relevant for 
cell transformation by EGFR variants.  
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 Constitutively phosphorylated at Y1068 and oriented correctly across the ER-membrane 
(Figure 2.3), EGFR Mut R1-6/L417H appears poised to requisition the canonical cytosolic 
signaling proteins that normally interact with EGF-stimulated EGFR. Adaptors that interact with 
pY1068, Grb2 and Gab2 (Rojas et al., 1996; Kong et al., 2000), lead to Ras-Erk/MAPK and 
PI3K pathways, respectively.  We found that EGFR Mut R1-6/L417H signals primarily through 
the PI3K pathway: Colony formation mediated by Mut R1-6/L417H EGFR is particularly 
sensitive to treatment with the PI3K inhibitor LY294002 (Figure 2.8B) and to mTOR inhibition 
by rapamycin (Figure 2.8D). Furthermore, we found that Akt is basally phosphorylated in EGFR 
Mut R1-6/L417H-expressing cells (Figure 2.8 A and B). In contrast, Erk phosphorylation is not 
increased in these cells compared to those expressing wt EGFR or vector only (Figure 2.9A). 
Although inhibition of Erk by PD98059 decreases colony formation mediated by EGFR Mut R1-
6/L417H, this decrease is similar to that for wt EGFR in the presence of EGF (Figure 2.9B), 
suggesting a contribution from endogenous EGFR to the transformation phenotype. Interestingly, 
EGFRvIII has been shown to signal similarly through the PI3K pathway, while only slightly 
activating the Ras-Erk/MAP kinase pathway (Moscatello et al., 1996, 1998). Determining how 
ER-retained EGFR mutants selectively commandeer the PI3K pathway merits further study. We 
note that all Ras isoforms are tethered to membranes through an isoprenyl moiety together with 
either palmitoylation or a polybasic sequence (Hancock et al., 1990). In contrast, PI3K and its 
downstream mediator Akt are cytosolic proteins, which are recruited through protein-protein or 
protein-lipid interactions. This disposition likely increases their intracellular accessibility for 
activation by ER-membrane-localized EGFR Mut R1-6/L417H or EGFRvIII receptors. Our 
results confirm that wholly ER-retained, constitutively active EGFRs can drive cellular 
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transformation. In a clinical context, cancers mediated by similarly retained mutant EGFRs will 
likely be more optimally treated by inhibitors that access their intracellular location. 
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Chapter 3 
PtdIns4P synthesis by PI4KIIIα  and its impact on proper 
biosynthetic protein trafficking 
 
3.1 Abstract 
The biosynthetic trafficking of receptors and other integral membrane proteins from the 
endoplasmic reticulum (ER) to the plasma membrane (PM) underlies the capacity of these 
proteins to participate in crucial cellular functions. Phosphoinositides have been shown to 
mediate distinct biological functions in cells, and phosphatidylinositol-4-phosphate (PI4P), in 
particular, has emerged as a key regulator of biosynthetic trafficking. To investigate the role of 
PI4P in orchestrating trafficking events, we developed a novel method to monitor the 
biosynthetic trafficking of transiently transfected proteins. We utilized pharmacological 
inhibition of different isoforms of PI 4-kinase to provide evidence for a distinct and necessary 
role for PI4P, synthesized by PI4KIIIα, in ER-to-PM trafficking. We complement our 
pharmacological studies with a genetic approach to deplete PI4P in the early biosynthetic 
pathway by overexpression of the Sac1 phosphatase. Taken together, these findings provide 
evidence that a specific pool of PI4P, synthesized by PI4KIIIα, plays a key role in biosynthetic 
trafficking of two different classes of proteins. 
 
3.2 Introduction 
Studies of the phosphorylated derivatives of phosphatidylinositol (PI) have shown that 
these molecules possess distinct biological functions and localize selectively to organelles 
(reviewed by Di Paolo and De Camilli, 2006). Due to variable phosphorylation of hydroxyl 
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groups on their inositol rings, seven different interconvertable phosphoinositide species exist in 
cells, including phosphatidylinositol-4-phosphate (PI4P) and phosphatidylinositol 4,5 
bisphosphate (PIP2). Each phosphoinositide species is enriched in specific intracellular 
membranes; for example, PI(4,5)P2 is highly localized to the inner leaflet of the PM, whereas 
PI4P is enriched at the Golgi complex.  
PI(4,5)P2 is a well-established regulator of multiple cellular processes including  vesicle 
trafficking, phagocytosis (Coppolino et al., 2002), membrane ruffling (Honda et al., 1999), cell 
motility, cell adhesion (Ling et al., 2002), and regulation of ion channel activity and receptor 
phosphorylation (Hilgemann et al., 2001; Michailidis et al., 2011). In addition, PI(4,5)P2 is the 
substrate for generation of the second messengers inositol tris-phosphate (IP3) and diacylglycerol 
(DAG) (Berridge, 1983), and is thus necessary for agonist-stimulated Ca2+ signaling. 
Furthermore, there have been several reports of PI(4,5)P2 existing in functionally and spatially 
distinct pools in the PM that support specific signaling platforms (Lui et al., 1998; Johnson et al., 
2008; Vasudevan et al., 2009; Calloway et al., 2011). PI4P, the most prevalent mono-
phosphorylated PI-derivative in cells (Lemmon, 2008), was for many years believed to serve no 
function outside of being the precursor for PIP2. Recently, however, a number of PI4P-dependent 
processes have been characterized, in particular its role in the regulation of protein trafficking 
(Figure 1.4). For example, PI4P is required to promote COPII-mediated ER export of proteins at 
ER exit sites (Blumental-Perry et al., 2006), and, by interacting with CERT, OSBP, and FAPP 
lipid transfer proteins (collectively termed COFs), PI4P also plays a role in sphingolipid and 
sterol metabolism (D’Angelo, 2008). 
Organelle specific phosphoinositide distributions are maintained by the tight regulation of 
PI-kinases and PI-phosphatases. Four distinct PI 4-kinases have been described in mammalian 
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cells, including type II (PI4KIIα and PI4KIIβ) and type III (PI4KIIIα and PI4KIIIβ) kinases 
(Balla and Balla, 2006). The type II PI-4kinases are palmitoylated (Barylko et al., 2001) and thus 
strongly membrane associated, particularly in the trans-Golgi apparatus (Wang et al., 2003) and 
to a lesser extent in endosomes (Balla et al., 2004). PI4KIIIβ localizes primarily to the Golgi 
apparatus (Wong et al., 1997), as detected by its coincidence with Arf1, a small GTP-binding 
protein (Godi et al., 1999). While the molecular details of how these enzymes are linked to 
Golgi-derived biosynthetic transport remain unknown, they have all been implicated with proper 
Golgi function and secretion (Balla and Ball, 2006). 
The predominant localization of PI4KIIIα is not well understood.  Mammalian PI4KIIIα 
is the homolog of yeast Stt4, a PM-associated protein (Audhya and Emr, 2002) that has more 
recently been suggested to localize to specific regions called PI-kinase (PIK) patches, important 
for signaling (Baird et al., 2008). Paradoxically, although Stt4 is not commonly detected in the 
ER in yeast, the PI4P pool generated by this kinase is mainly dephosphorylated by the ER-
localized phosphoinositide phosphatase, Sac1p (Foti et al., 2001).  The localization of PI4KIIIα 
to the ER is further supported by the presence of a FFAT (two phenylalanines [FF] in an acidic 
track) motif that binds to the integral ER proteins Scs2/22 in yeast, or VAP proteins in mammals 
(Stefan et al., 2011). In mammalian cells, PI4KIIIα has been reported to localize primarily to the 
ER based on immunofluorescence (Wong et al., 1997). However, more recent functional studies 
have called this localization into question.  For example, PI4KIIIα has been reported to be 
responsible for the generation of hormone-sensitive phosphoinositide pools in the PM (Balla et 
al., 2008) and the PI4P generated by the largely cytoplasmically localized PI4KIIIα has been 
proposed to play a major role in defining PM identity (Nakatsu et al., 2012).  
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Our results support the view that a pool of PI4P synthesized by PI4KIIIα is functionally 
required for proper ER-to Golgi trafficking. Using a novel technique that we designed to monitor 
biosynthetic trafficking, we demonstrate that pharmacological inhibition of PI4KIIIα results in 
ER-retention of both the epidermal growth factor receptor (EGFR) and a GPI-anchored protein. 
Furthermore, we demonstrate that specific inhibition of a Golgi-localized PI 4-kinase does not 
result in ER-retention. Finally, we show that depletion of PI4P via overexpression of the PI-
phosphatase Sac1 similarly inhibits protein trafficking to the PM. Taken together, these findings 
provide evidence that a specific pool of PI4P, synthesized by PI4KIIIα, is essential for proper 
biosynthetic protein trafficking. 
 
3.3 Materials and Methods 
3.3.1 Materials and Expression Plasmids 
 All cell culture reagents and all Alexa-dye conjugated secondary antibodies were from 
Invitrogen. FuGene HD was from Promega. The anti-N-terminal human EGFR antibody ((clone 
LA1) used for flow cytometry and immunochemistry) was from Millipore Corp. Anti-PDI 
(protein disulfide isomerase) mAb was from Affinity Bioreagents and the anti-GM130 was from 
BD Biosciences. PIK-93 was purchased from Symansis; wortmannin and brefeldin-A were from 
Calbiochem.  Anti-GFP mAb, phenylarsine oxide (PAO), quercetin as well as any chemical not 
noted otherwise were purchased from Sigma-Aldrich Chemical Co. The human EGFR-GFP 
construct has been described previously (Monick et al., 2005). The Sac1-GFP construct was 
kindly provided by Y. Mao (Cornell University). YFP-GPI is a GPI-anchored protein containing 
yellow fluorescent protein and a consensus N-glycosylation site fused to the GPI-attachment 
signal of lymphocyte-function-associated antigen 3 (LFA-3) (Keller et al, 2001). 
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3.3.2 Cell Culture 
RBL-2H3 mast cells were grown in MEM containing 20% (v/v) fetal bovine serum 
(FBS) (Atlanta Biologicals) and 10 µg/ml gentamicin sulfate as described previously (Gosse et 
al., 2005). In preparation for imaging or flow cytometry, cells were plated at 25-50% confluency 
in 35 mm MatTek wells (MatTek Corporation) or 60 mm dishes, respectively. After 
approximately 20 h, RBL-2H3 cells were transfected with either mutant or wild-type versions of 
EGFR. These constructs were transfected using Fugene HD (Promega) per manufacturers’ 
instructions, with modification to enhance transfection efficiency in the RBL cells previously 
described (Gosse et al., 2005). Cells were processed for imaging or flow cytometry 24 h after 
transfection. 
3.3.3 Biosynthetic Trafficking Method 
 On day one, approximately 1x106 RBL-2H3 cells were plated in 60mm dishes or 3.5x105 
RBL-2H3 cells were plated in 35-mm coverslip dishes (MatTek Corporation, Ashland, MA).  On 
day two, cells were transfected using Fugene HD as described above.  Cells were allowed to 
recover from transfection for 30 min to 1 hr at 37°C in normal RBL media before it was buffered 
with 40 mM HEPES, and the dishes were then sealed with parafilm and incubated at room 
temperature in the dark for 12 to 14 hr.  On day three, the media was changed to normal RBL-
2H3 media and cells were placed at 37°C; this point is time zero in the time course.  For most 
experiments (as denoted in legends), perturbants, diluted in BSS (BSS: 20 mM HEPES, 135 mM 
NaCl, 1.8 mM CaCl2, 2 mM MgCl2, 5.6 mM glucose, 1 mg/ml BSA, pH 7.4), were added at hour 
3 of the time course (media was replaced with BSS for control samples at this time in parallel). 
Samples from each time point were processed for confocal fluorescence microscopy or flow 
cytometry, as described below. 
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3.3.4 Confocal Fluorescence Microscopy 
 RBL-2H3 cells were washed once with BSS, fixed using 4% paraformaldehyde with 
0.1% gluteraldehyde, permeabilized (or not) with 1% v/v Triton X-100, and labeled for 1 hour 
with specified antibodies in phosphate buffered saline (PBS) with 10 mg/ml BSA and 0.01% w/v 
sodium azide (PBS/BSA). Images were collected using an upright Leica TCS SP2 laser scanning 
confocal microscope (Leica Microsystems, Exton, PA) with a 63 x 0.9 NA, HCX APO L U-V-I 
water-immersion objective. 
3.3.5 Flow Cytometry  
 RBL-2H3 cells were harvested, washed once with BSS, fixed using 4% 
paraformaldehyde with 0.1% glutaraldehyde, and washed once with PBS/BSA. Cells expressing 
GFP-tagged wild-type EGFR or YFP-GPI constructs were labeled with appropriate antibodies 
for 1 hr in PBS/BSA. Samples were evaluated using a Becton Dickinson LSR II flow cytometer, 
and data were analyzed using BD FACSDiva software. Analysis was gated to include single cells 
on the basis of forward and side light-scatter, and data from single-color samples were used to 
determine the gates for positive fluorescence from each fluorophore.  
3.3.6 Degranulation: β-Hexosaminidase Release 
 Cells were sensitized with IgE and plated in triplicate at a density of 5x105/well and 
incubated overnight.  The next day, cells were treated with PIK-93 (250nM or 1µM) for 40min 
in BBS without BSA, and β-hexosaminidase release was assessed as described previously (Naal 
et al., 2004). 
3.3.7 Data analysis 
Statistical analyses were determined using GraphPad Prism (GraphPad Software, La 
Jolla, CA), using the Student t test, with p ≤ 0.05 considered statistically significant. 
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3.4 Results 
3.4.1 Flow cytometry of transiently transfected cells to assess perturbations of early ER-to-
Golgi trafficking events.   
To manipulate the early stages of biosynthetic trafficking, we developed a protocol in 
which cells are incubated at 24°C for 14 hr following transient transfection with EGFR-GFP. 
This incubation at low temperature allows for protein synthesis to occur without subsequent 
trafficking to the PM.  The next day, the cells are transferred to 37°C, at which time biosynthetic 
trafficking begins and the increased presence of EGFR at the PM can be quantified over time 
(Figure 3.1A).  Representative confocal images of the flow cytometry samples (Figure 3.1A) 
show that following transfer to 37°C, it takes ~six hours until EGFR begins to accumulate visibly 
at the PM (Figure 3.1B).  In agreement with previous reports on the timescale of EGFR protein 
maturation (Verheijden et al., 1992), at 2 hr most cells show predominantly ER-localized EGFR, 
and by 4 hr significant Golgi localization is observed, with some receptor localization at the PM 
(Figure 3.1B).   
Preliminary experiments indicated that in order to observe the effects of potential 
inhibitors of ER-to-Golgi trafficking, a method in which a substantial percentage of transfected 
protein makes this transition at once is necessary.  To determine if our flow cytometry method 
was suitable, we first tested the effects of Brefeldin A (BFA), a well-documented inhibitor of 
early biosynthetic trafficking (Lippincott-Schwartz et al., 1989). Because we observed that 
EGFR transferred from ER to Golgi by 4 hr after the temperature shift, we chose to apply the 
inhibitor at 3 hr. When RBL cells expressing EGFR-GFP are treated with 5µg/ml BFA under 
these conditions the receptor is not trafficked to the PM (Figure 3.2A) but rather is retained 
intracellularly (Figure 3.2B).  Evidence that EGFR-GFP is retained in the ER in the presence of  
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Figure 3.1. Robust trafficking of EGFR to the PM is observed upon transferring expressing cells 
to 37°C following a 14 hr incubation at 24°C. (A) Live cells transiently expressing EGFR-GFP 
were fixed at each time point. Cells were labeled with an anti-N-terminal EGFR antibody 
followed by Alexa647-anti-IgG to label PM-associated EGFR, then analyzed by flow cytometry 
to determine the ratio of PM-localized EGFR fluorescence to total-EGFR fluorescence. Plot is 
representative of typical results; approximately 8,000 EGFR-GFP expressing cells were analyzed 
at each time point. (B) Representative images from time points quantified in A. 
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Figure 3.2. Treatment with Brefeldin A inhibits the biosynthetic trafficking of EGFR to the PM. 
Live cells transiently expressing EGFR-GFP were processed as described above (Fig. 3.1), aside 
from the addition of BFA (5µg/ml) to half of the cells at hour 3. (A) Flow cytometry was used to 
calculate the ratio of PM localized EGFR fluorescence to total EGFR fluorescence, and this ratio 
for each time point ± BFA is plotted. Error bars indicate ± SE of four independent experiments in 
which approximately 8,000 EGFR-GFP expressing cells were analyzed at each time point. ****, 
P<0.0001 (B) Confocal images of RBL cells expressing EGFR-GFP either untreated or treated 
with BFA, cells are from 8 hr time points quantified in A.  
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BFA is provided by immunofluorescent colocalization with the resident lumenal ER protein, 
protein disulfide isomerase (PDI) (Figure 3.6A). 
 
3.4.2 Inhibition of PI4KIIIα  abolishes the ability of EGFR to traffic from the ER to the 
Golgi apparatus. 
 We hypothesized that a pool of PI4P, generated by PI4KIIIα, is necessary for proper 
biosynthetic trafficking from the ER to the Golgi apparatus.  Phenylarsine oxide (PAO) is a well-
established inhibitor of PI 4-kinases (Wiedemann et al., 1996), which, when present in low 
micromolar concentrations, selectively inhibits the PI4KIIIα isoform (Balla and Balla, 2006). 
When RBL cells expressing EGFR-GFP are treated with 2.5 µM PAO, the receptors are not 
trafficked to the PM (Figure 3.3A) and concentrations as low as 1.5 µM substantially inhibit this 
biosynthetic trafficking (Figure 3.3B). The receptors are retained intracellularly (Figure 3.3C), 
primarily within the ER, coincident with PDI (Figure 3.6A).  
Although, low micromolar concentrations of PAO specifically inhibit the type-IIIα 
isoform of PI 4-kinase, PAO can also inhibit tyrosine phosphatases at these concentrations 
(Garcia-Morales et al., 1990).  To determine if the retention of EGFR in the ER upon PAO 
treatment is due to phosphatase inhibition, we tested the effects of the PI4-kinase inhibitors 
wortmannin and quercetin [2-(3,4-dihydroxy-phenyl)-3,5,7-trihydroxy-4H-chromen-4-one] on 
biosynthetic trafficking. Neither of these compounds also inhibit tyrosine phosphatases (Graziani 
et al., 1983; Nakanishi et al., 1994; Santos et al., 2013). Nanomolar concentrations of 
wortmannin have been shown to inhibit PI3-kinase (IC50=5nM) (Arcaro and Wymann, 1993),  
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Figure 3.3. Treatment with PAO inhibits the biosynthetic trafficking of EGFR to the PM in a 
dose-dependent manner. Live cells transiently expressing EGFR-GFP were processed as 
described above (Fig. 3.1), aside from the addition of PAO (concentration defined in legends) to 
half of the cells at hour 3. (A) Flow cytometry was used to calculate the ratio of PM localized 
EGFR fluorescence to total EGFR fluorescence, and this ratio for each time point ± PAO 
(2.5µM) is plotted. Error bars indicate ± SE of five independent experiments in which 
approximately 8,000 EGFR-GFP expressing cells were analyzed at each time point. ****, 
P<0.001 (B) Demonstration of dose-dependent effect of PAO on the biosynthetic trafficking of 
EGFR. Samples were processed as in A following addition of different concentrations of PAO 
(see legend). Plot is representative of typical results; approximately 8,000 EGFR-GFP expressing 
cells were analyzed at each time point. (C) Confocal images of RBL cells expressing EGFR-GFP 
either untreated or treated with PAO, cells are from 8 hr time points quantified in A.  
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whereas significantly higher concentrations are needed to similarly inhibit PI 4-kinases 
(Downing et al., 1996; Meyers and Cantley, 1997). We found that 10 µM wortmannin abolishes 
the capacity of EGFR-GFP to traffic to the PM (Figure 3.4A), and the receptor is visibly retained 
intracellularly (Figure 3.4B) in both the ER and the Golgi apparatus (Figure 3.6 A and B). When 
cells are treated with 200 nM wortmannin, EGFR-GFP biosynthetic trafficking to the PM is 
significantly reduced (Figure 3.4A); but still occurs visibly (Figure 3.4B). Quercetin has been 
shown to generally inhibit kinases, including PI kinases, by competition with ATP for the active 
site (Middleton et al., 2000). Quercetin treatment significantly reduces biosynthetic trafficking of 
EGFR in a dose dependent fashion (Figure 3.4 C), although some EGFR is detected at the PM by 
8 hr when cells are treated with 20 µM quercetin (Figure 3.4D). Inhibition of biosynthetic 
trafficking by PI kinase inhibitors wortmannin and quercetin (Figure 3.4) supports the contention 
that inhibition of trafficking with PAO (Figure 3.3) is preferentially due to the inhibition 
PI4KIIIα rather than tyrosine phosphatases. 
 Organelle-specific PI-kinases and phosphatases dictate distinct subcellular distributions 
of the individual PI species that control the timing and location of trafficking events (De Matteis 
and Godi, 2004). Based on immunofluorescence, PI4KIIIα has been suggested to localize to the 
ER (Wong et al., 1997), but a more recent study indicates a largely cytoplasmic distribution 
(Nakatsu et al., 2012). Both type-II PI 4-kinases localize to the Golgi complex and endosomes, 
and PI4KIIIβ localizes more selectively to the Golgi complex (Balla and Balla, 2006). To 
determine if inhibition of a different isoform of PI4K similarly inhibits biosynthetic trafficking 
of EGFR from the ER to the Golgi apparatus, we tested the effects of cis-Golgi localized 
PI4KIIIβ inhibition. PIK-93 (phenylthiazole) is a specific inhibitor of PI4KIIIβ (IC50=19nM)  
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Figure 3.4. Treatment with the PI4K inhibitors wortmannin and quercetin prevents the 
biosynthetic trafficking of EGFR to the PM. Live cells transiently expressing EGFR-GFP were 
processed as described above (Fig. 3.1), aside from the addition of wortmannin (200nM or 
10µM) or quercetin (20µM or 60µM) at hour 3. (A) Flow cytometry was used to calculate the 
ratio of PM localized EGFR fluorescence to total EGFR fluorescence, and this ratio for each time 
point ± wortmannin is plotted. Error bars indicate ± SE of five independent experiments in which 
approximately 8,000 EGFR-GFP expressing cells were analyzed at each time point. *, P<0.05; 
****, P<0.0001 (B) Representative confocal images of RBL cells expressing EGFR-GFP either 
untreated or treated with 200nM or 10µM wortmannin from 8hr time points quantified in A. (C) 
Flow cytometry was used to calculate the ratio of PM localized EGFR fluorescence to total 
EGFR fluorescence, and this ratio for each time point ± quercetin is plotted. Error bars indicate ± 
SE of four independent experiments in which approximately 8,000 EGFR-GFP expressing cells 
were analyzed at each time point. **, P<0.01 (D) Representative confocal images of RBL cells 
expressing EGFR-GFP either untreated or treated with 20µM quercetin from 8 hr time points 
quantified in C.  
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(Knight et al., 2006). We found that treatment with PIK-93 does not significantly affect the 
biosynthetic trafficking of EGFR-GFP, even when used at a concentration (1µM) which should  
completely inhibit PI4KIIIβ (Figure 3.5 A and B). To confirm that our PIK-93 stock inhibits 
PI4KIIIβ we assayed degranulation of RBL-2H3 cells in response to multivalent antigen. We 
find that PIK-93 reduces this stimulated degranulation by approximately 40% (Figure 3.5C), 
consistent with reduction in degranulation associated with PI4KIIIβ silencing (Kapp-Barnea et 
al., 2003).  
 
3.4.3 Depletion of PI4P by Sac1 phosphatase abolishes EGFR trafficking from the ER to 
the Golgi apparatus. 
The pharmacological effects described above point to a specific role of PI4P generated by 
PI4KIIIα in biosynthetic trafficking from ER to Golgi.  The only known lipid phosphatases with 
enzymatic activity towards PI4P are Sac1 homology domain-containing phosphoinositide 
phosphatases (Guo et al., 1999). The Sac1 protein is a transmembrane protein that localizes to 
the ER and Golgi membranes and performs organelle-specific roles in lipid signaling (Konrad et 
al., 2002). Thus, overexpressed Sac1 can serve as a genetic tool to deplete PI4P on the ER and 
Golgi membranes. We performed our biosynthetic trafficking protocol (Figure 3.1A) with cells 
transfected with both EGFR-GFP and Sac1-GFP, using a three-fold excess of Sac1 or vector 
DNA to EGFR DNA (Figure 3.7).  Sac1-GFP co-expression dramatically reduced the capacity of 
EGFR-GFP to traffic to the PM (Figure 3.7), further supporting the view that a pool of PI4P is 
important for ER-to-PM trafficking. 
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Figure 3.5. Treatment with PIK-93 does not significantly affect the biosynthetic trafficking of 
EGFR to the PM. Live cells transiently expressing EGFR-GFP were processed as described 
above (Fig. 3.1), aside from the addition of 1µM PIK-93 to half of the cells at hour 3. (A) Flow 
cytometry was used to calculate the ratio of PM localized EGFR fluorescence to total EGFR 
fluorescence, and this ratio for each time point ± PIK-93 is plotted. Error bars indicate ± SE of 
five independent experiments in which approximately 8,000 EGFR-GFP expressing cells were 
analyzed at each time point. n.s., not significant (B) Representative confocal images of RBL cells 
expressing EGFR-GFP either untreated or treated with 1µM PIK-93, cells are from 8hr time 
points quantified in A. (C) Degranulation is reduced in the presence of PIK-93. Cells were 
pretreated with denoted concentrations of PIK-93 for 40 min before stimulation with antigen (10 
µg/ml) for 25 min. Bars represent average degranulation response from one experiment. 
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Figure 3.6. Transiently expressed EGFR-GFP is retained within the ER of cells treated with 
BFA (5µg/ml) and PAO (2.5µM); whereas in cells treated with wortmannin (10µM) retention 
occurs in the ER and Golgi apparatus. (A) Attached RBL mast cells transiently expressing 
EGFR-GFP were processed as described above (Fig. 3.1), aside from the addition of inhibitors at 
hour 3. At hour 8 cells were fixed, permeabilized, and labeled with an anti-PDI antibody 
followed by Alexa555-anti-mouse IgG to label the ER. (B) The same cells shown in A were 
labeled with an anti-GM130 antibody followed by Alexa 647-anti-mouse IgG to label the Golgi 
apparatus. 
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Figure 3.7. Expression of Sac1-GFP inhibits the biosynthetic trafficking of co-expressed EGFR-
GFP to the PM. Live cells transiently expressing EGFR-GFP and Sac1-GFP were processed as 
described above (Fig. 3.1). Flow cytometry was used to calculate the ratio of PM localized 
EGFR fluorescence to total EGFR fluorescence, and this ratio for each time point plotted. Error 
bars indicate ± SD of two independent experiments in which approximately 2,000 double 
positive cells were analyzed at each time point.  
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3.4.4 The requirement of PI4P synthesized by PI4KIIIα  for ER-to-Golgi trafficking is not 
limited to EGFR or type-1 transmembrane proteins. 
The glycophosphatidylinositol (GPI) anchor is a posttranslational modification that 
anchors modified proteins to the outer leaflet of the PM (Ferguson et al., 1985).  Synthesis of the 
GPI-linker begins on the cytoplasmic face of the ER; the precursor is then flipped to the lumenal 
side of the ER for further processing and protein attachment before further trafficking to the PM 
(Orlean and Menon, 2007). We performed our biosynthetic trafficking protocol with a construct 
consisting of the GPI anchor of LFA-3, a heavily glycosylated surface protein of broad tissue 
distribution (Seed, 1987), fused to YFP.  In the hours following the temperature shift we observe 
increased PM presence of GPI-YFP, and this process is inhibited by treating the cells with 2.5 
µM PAO (Figure 3.8). This suggests that, PI4P synthesized by PI4KIIIα is involved in ER-to-
PM trafficking of two different classes of proteins. 
 
3.5 Discussion 
 Biosynthetic trafficking of receptors and other membrane proteins from the ER to the PM 
underlies the capacity of these proteins to participate in crucial cellular functions. Elucidating the 
mechanisms of the trafficking process is fundamental to understanding and interferring with the 
cellular responses that PM-localized receptors regulate. Herein, we describe a novel technique to 
examine the biosynthetic trafficking of transiently transfected proteins.  We utilized this 
technique to reveal the dependence on PI4P, synthesized by PI4KIIIα, for proper biosynthetic 
trafficking to the PM.  We took advantage of a number of well-characterized inhibitors of the 
different PI 4-kinase isoforms (Balla and Balla, 2006) to demonstrate that the type IIIα isoform 
synthesizes the relevant pool of PI4P.  We complemented our pharmacological studies with a  
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Figure 3.8. Treatment with PAO inhibits the biosynthetic trafficking of GPI to the PM. Live cells 
transiently expressing GPI-YFP were processed as described for EGFR expressing cells, PAO 
(2.5µM) was added to half of the cells at hour 3. (A) Flow cytometry was used to calculate the 
ratio of PM localized GPI fluorescence to total GPI fluorescence, and this ratio for each time 
point ± PAO (2.5µM) is plotted. Error bars indicate ± SD of three independent experiments in 
which approximately 2,000 GPI-YFP expressing cells were analyzed at each time point. **, 
P<0.01. (B) Confocal images of RBL cells expressing GPI-YFP either untreated or treated with 
PAO, cells are from 4.5 hr time points quantified in A.  
 
 
 
 
 
 
 
 
 
 
103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!"
!#$"
!#%"
!#&"
!#'"
!#("
!#)"
!#*"
!" $" %" &" '" ("
+,-./,0"
123"4%#(567"
Time (hours)!
PM
 G
PI
 F
luo
re
sc
en
ce
 / 
To
ta
l 
GP
I F
luo
re
sc
en
ce
!
** 
B
A
YFP-GPI!
Alexa 647 
Anti-GFP! Overlay!
Co
nt
ro
l!
PA
O 
2.
5µ
M
!
 
104 
 
genetic approach and showed that overexpression of the ER- and Golgi- localized PI4P 
phosphatase, Sac1, also abolishes protein trafficking to the PM. 
The discovery of mutant viral proteins such as vsvg-ts045 (vsvg: vesicular stomatitis 
virus glycoprotein) allowed for the study of synchronous transport of all of an overexpressed 
transmembrane protein throughout the biosynthetic pathway in a cell (Bergmann, 1989). In cells 
transfected with vsvg-ts045, the glycoprotein is synthesized at the non-permissive temperature 
but is not transported out of the rough endoplasmic reticulum. Upon a shift to the permissive 
temperature, however, the glycoprotein is rapidly and synchronously transported from the rough 
endoplasmic reticulum to the Golgi apparatus and then to the PM in a matter of two hours 
(Bergmann et al., 1981). Here we describe a method that allows for a similar experiment to be 
performed with any transiently transfected protein. Following transfection, cells are incubated 
overnight at room temperature. During this incubation, protein synthesis appears to occur 
without subsequent protein trafficking to the PM. The following day, when cells are shifted to 
37°C all of the synthesized protein moves through the biosynthetic pathway. In this study, we 
monitored the trafficking of EGFR (Figures 3.1 – 3.7) and a model GPI-linked protein (Figure 
3.8), both of which were fluorescently tagged and could be labeled with an extracellular epitope 
binding antibody to visualize the PM associated pool of protein over time. We used flow 
cytometry, complemented with confocal microscopy, to analyze this process. Biochemical 
methods, such as endoglycosidase H digestion could also be used with this general approach. 
We utilized this method to determine the importance of PI4P for biosynthetic trafficking 
by pharmacological inhibitors of the different isoforms of PI 4-kinase and by overexpressing a 
specific phosphatase.  We first verified that this system is sensitive to pharmacological 
intervention by testing the effects of the well-documented inhibitor of early biosynthetic 
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trafficking, BFA (Lippincott-Schwartz et al., 1989) (Figure 3.2). Of the different isoforms of PI 
4-kinase, PI4KIIIα is specifically inhibited by low micromolar concentrations of PAO (Balla and 
Balla, 2006).  When cells are treated with PAO in the context of our trafficking method, we 
observe a dose-dependent inhibition of biosynthetic trafficking of EGFR to the PM (Figure 3.3 A 
and B).  Maximal inhibition is attained for cells treated with 2.5µM PAO, and EGFR is retained 
in the ER (Figure 3.6A). To test the possibility that inhibition of biosynthetic trafficking by PAO 
is due to enzymes other than PI4KIIIα, we analyzed the effects of the less specific PI 4-kinase 
inhibitors, wortmannin and quercetin (Santos et al., 2013). Whereas nanomolar concentrations of 
wortmannin inhibit PI 3-kinase, wortmannin also inhibits PI 4-kinases at concentrations in the 
micromolar range (Balla et al., 1997). Quercetin has been shown to inhibit kinases by competing 
with ATP for binding (Middleton et al., 2000). We observe dose-dependent inhibition of 
biosynthetic trafficking, when cells expressing EGFR-GFP are treated with either wortmannin or 
quercetin (Figure 3.4), thus supporting the suggestion that PAO treatment inhibits biosynthetic 
trafficking by inhibiting PI4KIIIα. Due to the predominant localization of the other three PI4-
kinase isoforms to the Golgi, we believe that the perhaps spatially distinct pool of PI4P 
synthesized by PI4KIIIα may be important for biosynthetic trafficking.  This hypothesis is 
supported by the observation that inhibition of PI4KIIIβ does not significantly affect trafficking 
of EGFR to the PM (Figure 3.5). Because EGFR must transfer through the Golgi apparatus, we 
hypothesize that inhibition of one of these three Golgi-localized PI4-kinases is compensated for 
by the other PI4-kinases localized to this organelle. 
We hypothesize that PI4P mediates its effects on the biosynthetic trafficking of proteins 
via electrostatic interactions with basic stretches of protein sequence. Our laboratory recently 
showed that long chain sphingosine derivatives such as N,N’-dimethyl sphingosine (DMS) that 
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flip from the outer leaflet of the PM to its inner leaflet where they are protonated, are effective 
electrostatic competitors of proteins. The myristoylated alanine-rich C-kinase substrate effector 
domain (MARCKS ED), which is polybasic and binds to negatively charged phospholipids such 
as PIP2, can be competed off the PM with DMS treatment (Smith et al., 2010). In preliminary 
experiments, we find that DMS is an effective inhibitor of wt EGFR trafficking to the PM, 
causing EGFR to accumulate in the Golgi apparatus (Figure 3.9). We hypothesize that this 
accumulation occurs because transport vesicles do not leave the Golgi apparatus to fuse with the 
PM. Recently, D-sphingosine has been shown to inhibit exocytotic release of insulin and Glut4 
expression at the PM of pancreatic beta cells, and a similar electrostatic mechanism of inhibition 
has been implicated (Pessin et al., 2009). Smith et al. show that N,N’N”-trimethyl sphingosine 
(TMS) does not flip from the outer leaflet of the PM to the inner leaflet and hence does not 
electrostatically compete with protein binding (2010). We observe a lesser, yet significant, effect 
of TMS on appearance of protein at the PM (Figure 3.9), which may be complicated by effects 
on membrane curvature due to the insertion of the sphingosine and subsequent imbalanced 
expansion of the outer leaflet of the PM relative to the inner leaflet.   
A question currently under investigation in our laboratory is the location of this PI4P 
pool, which is important for biosynthetic trafficking and synthesized by PI4KIIIα. PI4KIIIα is a 
cytosolic protein and the subcellular membrane to which it primarily localizes has not been 
definitively determined (Nakatsu et al., 2013). Based on earlier studies, this enzyme has been 
reported to localize to the ER (Wong et al., 1997). However, this localization has not been 
supported by functional studies, which instead point to a role for PI4KIIIα in maintaining a pool 
of PI4P at the PM (Balla et al., 2008; Nakatsu et al., 2013). In terms of biosynthetic trafficking,  
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Figure 3.9. DMS treatment inhibits the biosynthetic trafficking of EGFR to the PM to a greater 
extent than treatment with TMS. Live cells transiently expressing EGFR-GFP were processed as 
described above (Fig. 3.1), aside from the addition of DMS or TMS (both 8µM) at hour 3. (A) 
Flow cytometry was used to calculate the ratio of PM localized EGFR fluorescence to total 
EGFR fluorescence, and this ratio for each time point ± DMS or TMS is plotted. Error bars 
indicate ± SD of three independent experiments in which approximately 8,000 EGFR-GFP 
expressing cells were analyzed at each time point and DMS data represent one experiment. *, 
P<0.05. (B) Representative confocal images of RBL cells expressing EGFR-GFP either 
untreated or treated with 8µM DMS or TMS, cells are from 8hr time points quantified in A.  
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PI4P localized to the Golgi apparatus has been routinely implicated in the delivery of cargos 
from the Golgi to the PM (Bruns et al., 2002; Szentpetery et al., 2010). However, a role for PI4P 
in COPII nucleation at ER-exit sites has also been reported (Blumental-Perry et al., 2006). We 
observe a primary accumulation of protein in the ER in cells in which PI4KIIIα has been 
inhibited (Figure 3.6A). It is possible that this accumulation is due to depletion of an ER-
localized pool of PI4P necessary for exiting the ER, or, alternatively, accumulation could result 
from depletion of a Golgi-localized pool of PI4P that results in retrograde trafficking to the ER. 
We complemented our pharmacological study with a genetic approach to deplete PI4P in 
the ER and Golgi.  We show that overexpression of the Sac1 phosphatase along with EGFR 
inhibits the biosynthetic trafficking of EGFR to the PM (Figure 3.6). The Sac1 phosphatase 
cycles between the ER and Golgi apparatus and is a key regulator of PI4P in mammalian cells 
(Blagoveshchenskaya et al., 2008). Szentpetery et al., described a drug-inducible molecular 
approach to specifically target the effects of Sac1 phosphatase activity to a particular 
intracellular membrane (2010). Efforts to employ this technique to deplete PI4P either in the ER 
or the Golgi apparatus, and thus determine the location of the pool of PI4P important for 
biosynthetic trafficking, are currently underway.  
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Chapter 4 
Summary and Future Directions 
 The juxtamembrane (JX) region of EGFR has recently emerged as a key regulator of 
receptor function (Red Brewer et al., 2009; Jura et al., 2009; Arkhipov et al., 2013). In 
November of 2008 we received a shipment from Dr. John Koland that contained an aliquot of 
EGFR-EGFP. Our laboratory’s interest in EGFR had been generated by our finding that mutation 
of three of the four basic residues within the polybasic JX region of the γ-subunit of a single 
chain chimeric fusion of FcεRI, completely abolished surface expression (Chapter 1). This result 
led to the hypothesis that basic residues located in the JX regions of transmembrane proteins play 
a role in ER-exit, perhaps by interacting with negatively charged lipids. EGFR is a Type I 
transmembrane protein that contains a polybasic JX region analogous to that of FcεRIγ (Sato et 
al., 2006). Our studies with EGFR began in order to test the generality of our hypothesis that 
such basic residues are important for ER to plasma membrane (PM) trafficking. We similarly 
mutated the basic residues in the JX region of EGFR, and by March of 2009 we already had a 
result to support our hypothesis. We had generated a mutant EGFR in which six of the nine JX 
basic residues were mutated to alanines and observed that this mutant was completely 
intracellularly retained.  
 While I performed experiments to further characterize the role of the basic JX residues in 
receptor trafficking, I began to wonder whether my ER-retained receptor was still capable of 
signaling. The guiding hypothesis for the studies with FcεRI was that reduction of the positive 
charge in the JX region of the receptor would relieve inhibitory interactions with negatively 
charged phosphoinositides in the PM and thus allow the receptor to constitutively activate. While 
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we had originally decided that the ER-retained phenotype precluded a study of the signaling 
capabilities of the receptor, I became very interested in determining if the ER-retained EGFR 
was capable of signaling and could transform cells. Following a summer sabbatical in the 
laboratory of Dr. Cerione, I had NIH 3T3 cells that stably expressed my different EGFR mutants, 
and on October 19, 2010 I recorded the results of my first anchorage independent growth assay 
that showed that my ER-retained EGFR JX mutant was capable of forming colonies in soft agar, 
independent of ligand addition. While I noted that I had only tested one clone in this experiment 
and would have to test more to confirm the result, the last line on the page of my lab notebook 
reads, “This could be the start of something beautiful.” 
 In July of 2012, we had written up a draft of a paper that described the beauty that evolved.  
The receptors were active and transforming cells from their ER locale. They were constitutively 
phosphorylated and preferentially signaled through the PI3K pathway. In the discussion, we tried 
to rationalize whether it was the ER-retention or the mutation of the basic residues that caused 
constitutive activation. As I began experiments aimed at answering that question, I was 
devastated (at the time) to discover that the JX mutation that I had made did not cause ER-
retention. In reality, a random mutation had occurred during the round of mutagenesis that 
generated my ER-retained mutant, and a single point mutation, L417H, was responsible for the 
ER-retention. 
 After I picked myself up and dusted myself off, I went about answering many of the 
questions that, a few months previously, we thought we couldn’t answer. The complete story 
comprises Chapter 2 of this thesis. While the road to where we are today was rocky, and there 
was somewhat of an earthquake at the end, it is amazing to think back to November 2008 when it 
began with an aliquot of EGFR-EGFP. We have acquired a large body of knowledge and 
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generated a substantial tool set that can be used to study what has become a hot topic in the 
EGFR field, the role of the JX region in the regulation of EGFR.  
 In terms of our current contributions to the field, our findings highlight the importance of 
the polybasic JX sequence in regulating the oncogenic potential of EGFR signaling. We found 
that charge-silencing mutagenesis within this JX region of EGFR results in the generation of a 
mutant receptor (EGFR Mut R1-6) that spontaneously transforms NIH 3T3 cells in a ligand-
independent manner. We also described a novel point mutation, L417H, which completely 
retains the receptor in the ER, and showed that the capacity of EGFR Mut R1-6 to mediate 
transformation is maintained when this mutant is retained in the ER. It is important to note that 
our study is the first to demonstrate that charge silencing mutagenesis within the polybasic JX 
region results in spontaneous activity. While others have differently mutated the JX region and 
shown decreased ligand-dependent activation (Hongbing et al., 2012; He and Hristova, 2012) in 
agreement with what we demonstrate in Appendix A, they do not report ligand independent 
activation. This could be due to the fact that their mutations to the JX region are not identical to 
ours. However, it could also be that they have not done the correct experiments to observe this 
phenotype. ER-retention and thus, perhaps, protection from PM localized phosphatases 
dramatically enhances the capacity to detect constitutive phosphorylation of the JX mutants by 
western blotting. In retrospect, if we had not generated EGFR Mut R1-6 L417H first, the 
enhanced basal phosphorylation would not have been as easily apparent. Therefore, the soft agar 
assays, where EGFR Mut R1-6 robustly transforms cells in a ligand independent manner, were 
critical in discovering this phenotype. To our knowledge, other groups who have recently 
reported different EGFR JX mutants have not performed such assays. 
 My work on EGFR has opened up a new vein of research in the Baird-Holowka laboratory 
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and I hope that future students continue these studies. One potential direction to go is better 
understanding of the basis for the ER-retention conferred by the L417H mutation. I have begun 
some preliminary work on this topic. Leucine 417 is located in domain III of the extracellular 
region of EGFR, which resembles a leucine-rich repeat (Bajaj et al., 1987; Ward and Garrett, 
2001). We hypothesized that replacement of leucine 417 with a histidine or alanine residue 
disrupts the closely packed hydrophobic core of the leucine-rich repeat, and this disruption 
results in a structural change, which in turn disallows the exit from the ER of EGFRs containing 
this mutation (Chapter 2). To determine if general disruption of the leucine-rich repeat causes 
ER-retention, I mutated other hydrophobic amino acids, within this area of the protein that are 
predicted to interact with leucine 417, including isoleucine 364 and leucine 448. I observed that 
both EGFR I364A and L448A were largely ER-retained; however, some protein was capable of 
trafficking to the PM. Thus, we believe that general disruption of this network of leucines can 
cause ER-retention; nevertheless, residue 417 is the only residue we have found thus far that 
when mutated completely precludes ER-exit. 
 These results support the contention that the L417H mutation disrupts the general fold of 
this region of the protein. I contend that this disruption is local and does not globally unfold the 
protein. This is supported by the fact that the transformation mediated by EGFR R1-6/L417H is 
inhibited by gefitinib, as, in order for that to be the case, the kinase domain must be intact. Also, 
we have shown that the receptors span the ER-membrane and hence have not been trafficked 
back into the ER lumen for degradation. However, the stabilities of our ER-retained mutants are 
routinely questioned, and thus I think it is important to determine the half-life of EGFR Mut R1-
6/L417H and EGFR L417H as compared to wt EGFR. Prior to leaving, I began these studies by 
treating cells with cyclohexamide to monitor protein degradation over time and assess whether 
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the ER-retained mutants are being degraded at a faster rate. Preliminary results suggest that over 
the course of 10 hours following the simultaneous application of cycloheximide and EGF 
(100ng/ml), EGFR L417H and EGFR Mut R1-6/L417H are not significantly degraded, whereas 
both wt EGFR and EGFR R1-6 are virtually eliminated from the cells. While a similar 
cycloheximide experiment must be performed in the future in the absence of EGF to assess basal 
degradation, our results thus far support the notion that EGFR L417H and EGFR MutR1-
6/L417H are not dramatically destabilized proteins. 
Another interesting question that we still do not understand is how EGFR R1-6/L417H 
becomes activated. Activation is constitutive and clearly is not triggered by ligand-dependent 
dimerization, as is the case for the PM-localized wt receptor. We are currently investigating the 
nature of this constitutive phosphorylated state, including the possibility that EGFR Mut R1-
6/L417H forms dimers in the ER. Interestingly, two of the mutated residues, arginine 651 and 
lysine 652, are involved in the formation of an antiparallel coiled-coil that is predicted to be 
important for the formation of active dimers (Jura et al., 2009). Activation independent of dimer 
formation has been suggested for EGFRvIII (Chu et al., 1997); thus, understanding the basis for 
activation of EGFR Mut R1-6/L417H could reveal a potentially novel mechanism for EGFR 
dimerization that could be more generally relevant for cell transformation by EGFR variants.  
To begin in this direction we must first determine whether the EGFR Mut R1-6/L417H 
dimerizes or not. I have initiated these studies by running unreduced samples on low percentage 
gels and western blotting for total and phosphorylated receptor. I detect a large molecular weight 
band that is present and phosphorylated, independent of ligand addition in lysates from cells 
expressing EGFR R1-6/L417H; this band is also present in lysates from EGF treated, wt EGFR 
expressing cells (Figure A3 and unpublished results). Thus, we hypothesize that this band 
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represents an oligomeric, possibly dimeric, EGFR species; however, we have not yet performed 
experiments in which we can accurately assess its molecular weight. This band decreases 
significantly in intensity upon reduction of the western blot samples, demonstrating that disulfide 
bonds are important for maintaining this species. In addition to these studies, Alice Wiesner has 
recently generated FLAG and HA-tagged wt EGFR and EGFR Mut R1-6/L417H constructs. 
Using these constructs we expect to demonstrate the presence or absence of dimerization by 
pulling down one transfected species and blotting for the other in the context of a co-IP. 
While the deduction of intracellular signaling cascades is not an easy task, especially 
when your receptor of interest can trigger many different pathways that can synergize, better 
understanding the signaling emanating from our JX mutant receptors could provide insight into 
the plasticity of EGFR signaling. We have shown that EGFR Mut R1-6/L417H exhibits basal 
tyrosine phosphorylation at residue Y1068 and that this signaling is particularly depends on PI3-
kinase and mTOR activity. While we show that EGFR Mut R1-6 mediated transformation is also 
sensitive to these inhibitors, it is not as sensitive as EGFR Mut R1-6/L417H. I hypothesize that 
because PI3K and its downstream mediator Akt are cytosolic proteins, which are recruited 
through protein-protein or protein-lipid interactions, this disposition likely increases their 
intracellular accessibility for activation by ER-membrane-localized EGFR Mut R1-6/L417H, and 
thus this pathway is particularly important for transformation mediated by this receptor.  
 EGFR Mut R1-6 is localized to the PM, and therefore in theory has access to all 
downstream partners that normally associate with wt EGFR. It is naïve to assume that EGFR 
Mut R1-6 signaling will be identical to its ER-retained counterpart. I have done some 
preliminary experiments showing that the JX mutant receptors are not solely phosphorylated at 
tyrosine 1068; both EGFR Mut R1-6 and EGFR Mut R1-6/L417H also appear to be 
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phosphorylated at tyrosine residues 845, 992, and 1173. While EGFR Mut R1-6 becomes 
phosphorylated at all these residues, it is generally less phosphorylated than EGF-stimulated wt 
EGFR and activates its downstream signaling partners to a lesser extent (Appendix A and 
unpublished results). The N-terminal halves of the JX region, which include residues that were 
mutated to alanines to generate EGFR Mut R1-6, have been shown to form an antiparallel helical 
dimer that stabilizes the formation of the TKD dimer (Jura et al., 2009). We hypothesize that 
dimerization at least contributes to EGFR Mut R1-6 activation, and therefore propose that the 
dimers might not be as stable because the receptor lacks certain basic residues. It is also possible 
that the constitutive activity of EGFR Mut R1-6 (Chapter 2) limits its capacity to mediate a 
maximal ligand-dependent response. While the level of constitutive activity is low in terms of 
receptor phosphorylation, this low level of continuous activation mediates robust ligand-
independent, anchorage-independent growth (Chapter 2). This capacity must be the result of the 
constitutive activation of downstream signaling partners, and it is possible that cell-wide 
constitutive activity changes the biology of the cellular environment in such a way that a 
maximal response is not possible following a bolus application of ligand. Determining the 
structural basis of EGFR Mut R1-6 activation and identifying its most immediate downstream 
signaling partners, independent of ligand, as well as following ligand addition, merits further 
study. 
 Historically, the story that became Chapter 3 of this thesis began when we were unaware 
of the L417H point mutation. At that time, we hypothesized that negatively charged 
phospholipids, particularly phosphatidylinositol 4-phosphate (PI4P), play an important role in 
biosynthetic trafficking, at least in part by electrostatic interactions with polybasic sequences 
often found in the cytoplasmic JX region of transmembrane proteins such as EGFR. To 
 
122 
 
complement the result that a charge-silenced JX mutant is ER-retained, we wanted to inhibit the 
production of ER-localized PI4P and similarly retain wt EGFR. Initially, we thought that our 
hypothesis was correct because treatment with micromolar PAO, which selectively inhibits the 
potentially ER-localized PI4KIIIα, results in ER-retention of EGFR. However, we realized that 
there was more to the story when we preformed a biosynthetic trafficking experiment with an 
EGFR construct in which the polybasic JX region was completely removed, and observed ER-
retention when we treated with PAO (unpublished results). This result encouraged us to test the 
effect of PAO treatment on other classes of proteins, and thus we found that GPI-linked protein 
trafficking is also inhibited by PAO. In the end, this study supports a dependence on PI4P, 
synthesized by PI4KIIIα, for proper biosynthetic trafficking of two different classes of proteins 
to the PM. 
 My successors could further  enhance this story by  complementing the pharmacology of 
Chapter 3 with a genetic approach to deplete PI4P in the ER. We demonstrate that co-expression 
of the PI-4P phosphatase, Sac1-GFP, and EGFR-GFP in the context of our biosynthetic 
trafficking protocol inhibits the trafficking of EGFR-GFP (Chapter 3). However, a potential 
lurking artifact in this experiment is the possibility that merely the expression of another ER-
localized protein contributes significantly to the inhibition of trafficking. I have observed this 
with a number of other constructs and further experiments are necessary to determine if that 
same artifact is contributing in the Sac1-GFP experiments. Another approach that I have initiated 
is knocking down PI4KIIIα. There are a number of technical challenges associated with this 
experiment. These include: the fact that we are using RBL-2H3 cells that notoriously do not 
transfect well; and the discrepancy between optimal knockdown with siRNA typically occurring 
2-3 days post transfection, and the requirement that the protein of interest in a biosynthetic 
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trafficking experiment be transfected one day prior to the experiment. Potentially, a three-color 
flow experiment in which siRNA positive cells are marked with one color and two other colors 
are used to label the total and PM-localized EGFR pools is the answer to this problem; however, 
more planning and new reagents are required before this experiment can be performed. 
 I expect that the biosynthetic trafficking assay that we designed in order to perform the 
experiments described in Chapter 3 will be particularly valuable to others working in this field. 
While synchronous transport throughout the cellular biosynthetic pathway can be studied using 
specially designed constructs such as vsvg-ts045 or specialized microscopy techniques; our 
protocol is unique in that it can theoretically be performed with any fluorescently tagged protein 
with a detectable extracellular epitope. In the future, we could expand the repertoire of protein 
classes that can be studied using this technique by attempting to monitor the trafficking of a 
multi-pass transmembrane protein. We began collecting the necessary reagents for this 
experiment and thus acquired an Orai1 construct with a HA-tag inserted in an extracellular loop; 
once this construct is fluorescently tagged, it would be ready to be tested. I used this protocol to 
demonstrate the dependence of biosynthetic trafficking from the ER to the Golgi on PI4P. In 
addition, it could be modified in countless ways to study different steps in the biosynthetic 
pathway as well as the effects of different classes of inhibitors. 
 In conclusion: Herein, I have described in Chapter 2 the generation of an EGFR mutant in 
which the net charge of the JX region has been reduced from +8 to +3, due to the mutation of 
basic residues to alanines.  This receptor (Mut R1-6) is constitutively active, and we hypothesize 
that this is due to the release of inhibitory protein-lipid interactions that hold the receptor in an 
inactive conformation. I also discovered that a single point mutation, L417H, causes retention of 
EGFR in the ER, and I showed that when EGFR Mut R1-6/L417H is constitutively expressed it 
 
124 
 
is capable of transforming cells, in particular by signaling through PI3K and mTOR.  In Chapter 
3, I demonstrated the importance of PI4P in the biosynthetic trafficking of two classes of 
proteins. Biosynthetic trafficking of receptors and other transmembrane proteins from the ER to 
the PM underlies the capacity of these proteins to participate in crucial cellular functions, and 
this work adds to the body of literature describing the importance of phosphoinositides in 
regulating this process. In the Appendix, I revisit the EGFR JX mutants and demonstrate that 
ablating electrostatic interactions of the JX region with the PM changes their capacity for ligand-
dependent signaling as compared to wt EGFR. 
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Appendix 1 
 
Charge-silencing Mutations in the Polybasic Juxtamembrane 
Sequence of the EGF Receptor Alters its Capacity for Ligand-
Dependent Signaling 
 
A.1 Introduction 
 The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that plays 
important roles in cell differentiation, proliferation, and epithelial organogenesis (Carpenter, 
2000). To maintain normal cellular homeostasis, EGFR signaling must be tightly regulated. Loss 
or disruption of this regulation can lead to cellular abnormalities such as oncogenic 
transformation (Blume-Jensen and Hunter, 2001).  
 EGFR is an integral membrane protein consisting of an extracellular ligand-binding 
segment, a single transmembrane segment, and an intracellular segment consisting of a 
juxtamembrane (JX) region, a tyrosine kinase domain (TKD), and a C-terminal tail. Signaling by 
EGFR is initiated following its ligand-induced dimerization, which leads to TKD-dependent 
phosphorylation of the C-terminal segments of two interacting receptors (Schlessinger, 2000). 
The JX region of EGFR has recently emerged as a key regulator of receptor function, and the 
current model for TKD activation can no longer be discussed without describing its involvement. 
The TKDs form an asymmetric dimer in which one activates the other, and the C-terminal halves 
of the JX regions of the receiver TKD form a clasp that promotes this asymmetric activation 
(Red Brewer et al., 2009; Jura et al., 2009). The N-terminal halves of the JX region that include a 
polybasic sequence stabilize this interaction via the formation of an antiparallel helical dimer 
(Jura et al., 2009). 
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 The JX region of EGFR has also been implicated in maintaining the unliganded receptor 
in an inactive state. Recent evidence suggests that the basic residues in the N-terminal JX region 
associate electrostatically with negatively charged phospholipids to facilitate insertion of 
adjacent hydrophobic leucine side chains into the PM bilayer in inactive EGFR. The leucine side 
chains are then expelled during formation of the helical dimer in the active state (Endres et al., 
2013; Arkhipov et al., 2013). In Chapter 2, we demonstrated that reduction of the net charge in 
the JX region of wild-type (wt) EGFR results in a receptor (EGFR Mut R1-6) that is 
constitutively active and capable of ligand independent cell transformation. 
 The phosphorylated tyrosines on the C-terminal tail of EGFR act as docking sites for 
adaptor molecules that link the receptor to downstream pathways. A multitude of pathways 
emanate from EGFR including the Ras/MAPK/ERK pathway, the PI3K-Akt pathway, and Ca2+ 
mobilization mediated by PLCγ, which is the focus of this study. Activation of EGFR leads to 
phosphorylation of the receptor at tyrosine residue 992 and subsequent recruitment of 
PLCγ (Emlet et al., 1997). Upon phosphorylation and activation, PLCγ hydrolyzes PI(4,5)P2 to 
form the second messengers inositol trisphosphate (IP3) and  diacylglycerol (DAG) (Berridge, 
1983). IP3 interacts with the IP3 receptor in the ER to mediate release of Ca2+ from ER stores. 
Elevated Ca2+ binds to calmodulin, which in turn activates Ca2+/calmodulin-dependent protein 
kinases. Meanwhile, DAG, in concert with Ca2+, activates protein kinase C (PKC).  PKC 
activation leads to phosphorylation and activation of transcription factors (Karin and Hunter, 
1995). 
 Motivated by the hypothesis that a receptor with diminished positively charged residues 
in the JX region (EGFR Mut R1-6) would have different capacities for signaling in response to 
ligand, we find that EGFR Mut R1-6 exhibits a reduction in the magnitude of its Ca2+ response 
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compared to wt EGFR. In addition, we show that EGFR Mut R1-6 exhibits reduced 
phosphorylation of tyr 992 as compared to wt EGFR, corresponding to decreased downstream 
activation of PLCγ and ERK. While the mechanism for this observation is still under study, we 
provide preliminary evidence that EGFR Mut R1-6 receptors have reduced capacity to form 
higher order oligomeric signaling complexes that may be necessary for the optimal activation of 
downstream signaling partners. 
 
A.2 Materials and Methods 
A.2.1 Materials and Plasmids 
 All cell culture reagents, EGF, and precast gels for blotting were from Invitrogen. 
FuGene HD was from Roche Applied Sciences. PVDF membranes were from Millipore Corp. 
The antibodies that recognize the phosphorylated forms of Erk and PLCγ-1 (Y783), as well as 
phospho-specific EGFR antibody (Y1068), phospho-specific EGFR antibody (Y992), and the 
anti-EGFR (used for blotting) were from Cell Signaling. The anti-actin antibody was from 
LabVision/Thermo. HRP-conjugated secondary antibodies used for blotting were from GE 
Healthcare. The R-GECO-1 was purchased from AddGene. 
A.2.2 Cell Culture 
Generation of the stable cell lines used for blotting experiment was described in Chapter 
2. RBL-2H3 mast cells were grown in MEM containing 20% (v/v) fetal bovine serum (FBS) 
(Atlanta Biologicals) and 10 µg/ml gentamicin sulfate as described previously (Gosse et al., 
2005). Mouse NIH 3T3 cells were grown in DMEM containing 10% (v/v) calf serum (CS). 
A.2.3 Intracellular Ca2+ Measurements of Suspended cells 
In preparation for transfection, cells were plated at 50% confluency into 6-well plates 
 
129 
 
(Falcon). After approximately 20 h, RBL-2H3 cells were transfected with either mutant or wild-
type versions of EGFR, as well as the R-GECO1 Ca2+ sensor. These constructs were transfected 
using Fugene HD (Roche) per manufacturers’ instructions, with modification to enhance 
transfection efficiency in the RBL cells previously described (Gosse et al., 2005). Cells were 
processed for fluorimetry 24 h after transfection. 
Cells were harvested in PBS/EDTA and suspended in buffered saline (BS: 20 mM 
HEPES, 135 mM NaCl, 1.8 mM CaCl2, 2 mM MgCl2, 5.6 mM glucose, pH 7.4). Time-based 
acquisition of cytoplasmic Ca2+ responses was monitored using a SLM 8100C fluorimeter, and 
cells were stimulated with 100 ng/ml EGF. Stimulated Ca2+ responses were normalized using 
total R-GECO1 fluorescence following cell lysis by addition of 0.1% Triton X-100 minus total 
fluorescence in the presence of excess EDTA as previously described (Vasudevan et al., 2009).  
A.2.4 Immunoblot Analysis 
After treatment (or not) with EGF (100 ng/ml) for 5min (unless otherwise specified), 
cells were washed in PBS, incubated in lysis buffer (25mM Tris, pH7.4, 100mM NaCl, 1mM 
EDTA, 1% (v/v) Triton 100, 1mM DTT, 1mΜ sodium orthovanadate, 1mM β-glycerol 
phosphate, 1µg/mL leupeptin, and 1µg/mL aprotinin), and supernatants were retained following 
microfuge centrifugation. Protein concentrations of the whole-cell lysates (WCL) were 
determined using the Bio-Rad DC protein assay. WCL (20-35 µg/lane) were resolved by 
SDS/PAGE, and the proteins were transferred to PVDF membranes. Membranes were blocked 
by 10% (w/v) BSA in 20 mM Tris, 135 mM NaCl, and 0.02% Tween 20, then incubated with the 
indicated primary antibodies diluted in the same buffer. The primary antibodies were detected 
with HRP-conjugated secondary antibodies followed by exposure to ECL reagent (Invitrogen).  
 
 
130 
 
A.2.5 Data analysis 
Analysis and quantification of signal from western blots was conducted using Image J 
(National Institutes of Health). Statistical analyses were determined using GraphPad Prism 
(GraphPad Software, La Jolla, CA), using the Student t test, with p ≤ 0.05 considered statistically 
significant.  
 
A.3 Results 
A.3.1 Cells expressing juxtamembrane mutant R1-6 exhibit decreased EGF-stimulated 
Ca2+ mobilization. 
To investigate potential roles of basic JX residues in receptor-mediated cell signaling, we 
focused on the polybasic JX region of EGFR (McLaughlin, 2005; Sengupta 2009).  In a previous 
study, we demonstrated that charge silencing within the JX sequence of EGFR results in 
constitutive activation of the receptor (Chapter 2). We sequentially mutated basic residues in this 
sequence to alanines, reducing the net charge of the JX region from +8 to +3 (EGFR Mut R1-6), 
and we showed that this mutated receptor is basally phosphorylated at tyrosine 1068 and is 
capable of mediating ligand-independent, anchorage-independent growth. Furthermore, 
phosphorylation and anchorage independent growth are enhanced in the presence of EGF 
(Chapter 2).   
To investigate the importance of these basic residues in the JX region of EGFR in ligand-
dependent signaling, we measured Ca2+ levels in suspended RBL-2H3 cells transiently 
expressing wt EGFR or Mut R1-6 EGFR using the genetically encoded Ca2+ probe R-GECO-1 
(red intensiometric genetically encoded Ca2+-indicators for optical imaging) (Zhao et al., 2011). 
RBL-2H3 cells do not express endogenous EGFR, and thus RBL-2H3 cells not ectopically 
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expressing EGFR do not display an EGF-mediated Ca2+ response (data not shown). As shown in 
Figure A.1 A-C, EGF stimulates a biphasic Ca2+ response that is significantly larger and faster 
for the wt EGFR-expressing cells as compared to the Mut R1-6 expressing cells. When multiple 
experiments are averaged, the Mut R1-6 expressing cells exhibit a peak response that is about 
35% of the magnitude of the stimulated wt response (Figure A.1D). 
 
A.3.2 Juxtamembrane mutant R1-6 receptors are not efficiently phosphorylated in 
response to EGF and demonstrate decreased signaling through PLC-γ  and ERK. 
 We investigated whether EGFR Mut R1-6 is phosphorylated in response to EGF and the 
extent to which it activates the downstream signaling partners necessary for Ca2+ mobilization. 
We observed less EGF-stimulated phosphorylation of EGFR Mut R1-6 by western blotting of 
whole-cell lysates from NIH3T3 cells stably expressing this mutant receptor, using an anti-
phospho-EGFR (Y992) antibody (Figure A.3A). This trend is evident in multiple clones 
expressing similar levels of wt or Mut R1-6 receptor (Figure A.3A), and is also observable using 
an anti-phospho-EGFR (Y1068) antibody (data not shown).  
 To determine the capacity of Mut R1-6 to signal to downstream partners, we focused our 
investigation on proteins that interact with EGFR via phospho-Y992, including PLCγ-1. Figure 
A.2 summarizes results comparing the activity of this protein, as well as ERK, in NIH 3T3 cells 
stably expressing wt EGFR to those expressing EGFR Mut R1-6. Cells expressing EGFR Mut 
R1-6 exhibit decreased levels of activated PLCγ-1 (Y783) as compared to wt EGFR expressing 
cells in response to EGF treatment (Figure A.3 A and B). Furthermore, decreased levels of 
activated ERK are also observed in cells expressing EGFR Mut R1-6 as compared to cells 
expressing wt EGFR (Figure A.2 C and D). These results provide a consistent picture that the  
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Figure A.1. Ca2+ responses to EGF for RBL-2H3 cells transiently expressing wt EGFR and 
EGFR Mut R1-6. (A) Trace shows representative Ca2+ response for RBL-2H3 cells transiently 
expressing wt EGFR stimulated with 100ng/ml EGF from one experiment. (B) Trace shows 
representative Ca2+ response for RBL-2H3 cells transiently expressing EGFR Mut R1-6, treated 
as in A. (C) Overlay of traces shown in A and B. (D) Quantification of Ca2+ response for RBL-
2H3 cells transiently expressing wt EGFR and EGFR Mut R1-6. Peak Ca2+ responses in the 
presence of extracellular calcium were averaged from three independent experiments including 
that shown in A-C (error bars show S.D., **, P<0.01). 
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Figure A.2. EGFR Mut R1-6 receptors exhibit reduced phosphorylation and downstream 
signaling through PLC-γ and ERK. (A) Whole cell lysates from serum-starved NIH 3T3 cells 
stably expressing wt or Mut R1-6 EGFR and treated with EGF (100ng/ml) for 5 min as 
indicated, were immunoblotted with antibodies specific for total EGFR, phospho-EGFR Y992, 
phospho-PLCγ1 Y783, or actin (loading control). (B) Quantification of PLCγ1 phosphorylation 
in cells expressing wt EGFR or EGFR Mut R1-6 in the presence of EGF for 5 min. Data were 
averaged from seven independent experiments including that shown in A and C (error bars show 
S.E., ****, P<0.0001). (C) Whole cell lysates from serum-starved NIH 3T3 cells stably 
expressing wt or Mut R1-6 EGFR and treated with EGF (100ng/ml) in the context of a time 
course as indicated (- = no EGF, otherwise time in presence of EGF is shown), were 
immunoblotted with antibodies specific for phospho-EGFR Y992, phospho-PLCγ1 Y783, or 
phospho-ERK. (D) Quantification of ERK phosphorylation in cells expressing wt EGFR or 
EGFR Mut R1-6 in the presence of EGF. Data were averaged from five independent experiments 
including that shown in C (error bars show S.E., ***, P<0.001). 
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decreased Ca2+ mobilization observed for EGFR Mut R1-6-expressing cells is due to its inability 
to maximally activate the downstream signaling partners necessary for this response. 
 
A.4 Discussion 
 The results presented in this Appendix provide evidence that the polybasic JX region of 
EGFR plays a positive role in ligand-dependent signaling. We have previously reported that 
reduction of the net charge of the JX region of EGFR from +8 to +3 results in the constitutive 
activation of the receptor (Chapter 2). Herein, we focus on the response of this mutant receptor 
(EGFR Mut R1-6) to EGF and its ability to communicate with the downstream signaling partners 
necessary for Ca2+ mobilization. We find that activation of EGFR Mut R1-6 results in a delayed 
and significantly attenuated Ca2+ response (Figure A.1). Consistent with this observation, we 
show that EGFR Mut R1-6 is sub-optimally phosphorylated in response to EGF and does not 
activate PLCγ and ERK as efficiently as wt EGFR (Figure A.2).  
 The ~37-residue JX region of EGFR has emerged as a key regulator of receptor function 
(Red Brewer et al., 2009; Jura et al., 2009; Arkhipov et al., 2013). In addition to interacting with 
acidic phospholipids (McLaughlin et al., 2005; Sengupta et al., 2009; Michailidis et al., 2011), 
several intrinsic sorting signals have been mapped to this JX region (Morrison et al., 1996; He et 
al., 2002), which also contains a basic calmodulin (CaM) binding sequence (Martin-Nieto and 
Villaobo, 1998). CaM is a major component of many Ca2+-signaling pathways and mediates the 
activity of multiple effectors. It has been proposed the CaM directly interacts with the polybasic 
JX region of EGFR and that ablation of these residues results in decreased activation of PLCγ in 
response to EGF (Li et al., 2012). We are currently investigating whether EGFR Mut R1-6 has 
the capacity to interact with CaM. 
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 EGFR Mut R1-6 is not only deficient in its ability to activate downstream signaling 
partners, these receptors also do not transphosphorylate to the same extent as wt EGFRs. We 
observed this trend when blotting with antibodies specific for either phosphorylation at tyrosine 
992 (Figure A.2) or tyrosine 1068 (data not shown).  The N-terminal halves of the JX region, 
which include residues that were mutated to alanines to generate EGFR Mut R1-6, have been 
shown to form an antiparallel helical dimer that stabilizes the formation of the TKD dimer (Jura 
et al., 2009). We have not yet determined whether EGFR Mut R1-6 activation  depends on 
dimerization; however, because its signaling is enhanced in the presence of ligand (Figure 2.5C), 
we hypothesize that dimerization at least contributes to its activation.  
 We have identified a large molecular weight band that is visible when blotting non-
reduced whole cell lysates from cells that stably express wt and Mut R1-6 EGFR (Figure A.3). In 
wt EGFR expressing cells, the presence of this band depends on the addition of EGF, and it is 
detectable with both a total EGFR antibody (data not shown) and antibodies specific for EGFR 
phosphorylated at tyr 992 (Figure A.3) and tyr 1068 (data not shown). We hypothesize that this 
band represents EGFR dimers or higher order oligomers. Interestingly, while phosphorylation of 
EGFR Mut R1-6 as represented by the monomer band at approximately 180kDa is reduced as 
compared to wt (Figure A.2 A and C; Figure A.3); the signal from this upper molecular weight 
band is almost entirely abolished in mutant expressing cells (Figure A.3). This band is visible 
when lysates are probed with an antibody that recognizes total EGFR; however, further 
quantifiable experiments must be done to determine if the presence of this band is generally 
reduced in EGFR Mut R1-6 expressing cells. It has been proposed that higher order oligomers 
and microclusters of EGFR are necessary for maximal activation and robust downstream 
signaling (Clayton et al., 2007). We are interested in determining if the inability of EGFR Mut  
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Figure A.3. EGFR Mut R1-6 receptors exhibit negligible phosphorylation of an upper molecular 
weight band in response to EGF. (A) Unreduced whole cell lysates from serum-starved NIH 3T3 
cells stably expressing wt or Mut R1-6 EGFR and treated with EGF (100ng/ml) as indicated 
(numbers represent minutes in the presence of EGF) were immunoblotted with an antibody 
specific for phospho-EGFR Y992. U= upper band and M= monomer band. (B) Quantification of 
phospho-EGFR Y992 intensity from blot in A. Data were normalized to the phosphorylation 
seen 2 min post-EGF addition for the corresponding U and M wild-type EGFR samples. WT= 
wild type EGFR and R1-6= EGFR Mut R1-6, M= monomer band at ~180kDa, and U= upper 
band. 
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R1-6 receptors to form stable dimers or higher order oligomers underlie their reduced capacity 
for downstream signaling, even in the presence of EGF. 
 Finally, it is also possible that the constitutive activity of EGFR Mut R1-6 (Chapter 2) 
underlies it inability to mediate a maximal ligand-dependent response. While the level of 
constitutive activity is low in terms of receptor phosphorylation, this low level of continuous 
activation mediates robust ligand-independent, anchorage-independent growth (Chapter 2). This 
ability must be the result of the constitutive activation of downstream signaling partners. It is 
possible that cell-wide constitutive activity changes the biology of the cellular environment in 
such a way that a robust response is not possible in response to a bolus application of ligand. We 
are currently pursuing this alternative mechanistic explanation for our observations. 
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